

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 10-Q

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended **September 30, 2021**

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_.

Commission file number: **001-37815**

**Global Medical REIT Inc.**

(Exact name of registrant as specified in its charter)

<b>Maryland</b> (State or other jurisdiction of incorporation or organization)	<b>46-4757266</b> (I.R.S. Employer Identification No.)
---	---

<b>2 Bethesda Metro Center, Suite 440</b> <b>Bethesda, MD</b> (Address of principal executive offices)	<b>20814</b> (Zip Code)
--	----------------------------

Registrant's telephone number, including area code: **(202) 524-6851**

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	Trading Symbols:	Name of each exchange on which registered:
Common Stock, par value \$0.001 per share	GMRE	NYSE
Series A Preferred Stock, par value \$0.001 per share	GMRE PrA	NYSE

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

The number of shares of the registrant's common stock outstanding at November 1, 2021 was **64,207,923**.

**TABLE OF CONTENTS**

**PART I FINANCIAL INFORMATION**

<a href="#">Item 1.</a>	<a href="#">Financial Statements (Unaudited)</a>	
	<a href="#">Condensed Consolidated Balance Sheets – September 30, 2021 and December 31, 2020</a>	3
	<a href="#">Condensed Consolidated Statements of Operations – Three and Nine Months Ended September 30, 2021 and 2020</a>	4
	<a href="#">Condensed Consolidated Statements of Comprehensive Income (Loss) – Three and Nine Months Ended September 30, 2021 and 2020</a>	5
	<a href="#">Condensed Consolidated Statements of Equity – Three and Nine Months Ended September 30, 2021 and 2020</a>	6
	<a href="#">Condensed Consolidated Statements of Cash Flows –Nine Months Ended September 30, 2021 and 2020</a>	8
	<a href="#">Notes to the Unaudited Condensed Consolidated Financial Statements</a>	9

<a href="#">Item 2.</a>	<a href="#">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a>	37
-------------------------	---	----

<a href="#">Item 3.</a>	<a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>	51
-------------------------	--	----

<a href="#">Item 4.</a>	<a href="#">Controls and Procedures</a>	52
-------------------------	---	----

**PART II OTHER INFORMATION**

<a href="#">Item 1.</a>	<a href="#">Legal Proceedings</a>	52
-------------------------	-----------------------------------	----

<a href="#">Item 1A.</a>	<a href="#">Risk Factors</a>	52
--------------------------	------------------------------	----

<a href="#">Item 2.</a>	<a href="#">Unregistered Sales of Equity Securities and Use of Proceeds</a>	53
-------------------------	---	----

<a href="#">Item 3.</a>	<a href="#">Defaults Upon Senior Securities</a>	53
-------------------------	---	----

<a href="#">Item 4.</a>	<a href="#">Mine Safety Disclosures</a>	53
-------------------------	---	----

<a href="#">Item 5.</a>	<a href="#">Other Information</a>	53
-------------------------	-----------------------------------	----

<a href="#">Item 6.</a>	<a href="#">Exhibits</a>	54
-------------------------	--------------------------	----

<a href="#">Signatures</a>		55
----------------------------	--	----

**GLOBAL MEDICAL REIT INC.**  
**Condensed Consolidated Balance Sheets**  
**(unaudited and in thousands, except par values)**

	As of	
	September 30, 2021	December 31, 2020
<b>Assets</b>		
Investment in real estate:		
Land	\$ 149,249	\$ 128,857
Building	964,169	851,427
Site improvements	18,017	15,183
Tenant improvements	56,156	49,204
Acquired lease intangible assets	123,918	98,234
	1,311,509	1,142,905
Less: accumulated depreciation and amortization	(130,284)	(94,462)
Investment in real estate, net	1,181,225	1,048,443
Cash and cash equivalents	6,030	5,507
Restricted cash	5,839	5,246
Tenant receivables, net	5,126	5,596
Due from related parties	275	103
Escrow deposits	5,970	4,817
Deferred assets	24,422	20,272
Derivative asset	219	—
Goodwill	5,903	5,903
Other assets	8,297	5,019
Total assets	<u>\$ 1,243,306</u>	<u>\$ 1,100,906</u>
<b>Liabilities and Equity</b>		
Liabilities:		
Credit Facility, net of unamortized debt issuance costs of \$ 8,497 and \$3,559 at September 30, 2021 and December 31, 2020, respectively	\$ 497,203	\$ 521,641
Notes payable, net of unamortized debt issuance costs of \$644 and \$835 at September 30, 2021 and December 31, 2020, respectively	57,397	64,937
Accounts payable and accrued expenses	11,065	7,279
Dividends payable	15,309	12,470
Security deposits	4,600	4,340
Derivative liability	12,070	18,086
Other liabilities	7,104	6,171
Acquired lease intangible liability, net	8,333	8,222
Total liabilities	<u>613,081</u>	<u>643,146</u>
Commitments and Contingencies		
Equity:		
Preferred stock, \$0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at September 30, 2021 and December 31, 2020, respectively (liquidation preference of \$77,625 at September 30, 2021 and December 31, 2020, respectively)	74,959	74,959
Common stock, \$0.001 par value, 500,000 shares authorized; 64,208 shares and 49,461 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	64	49
Additional paid-in capital	700,206	504,789
Accumulated deficit	(147,562)	(116,773)
Accumulated other comprehensive loss	(11,946)	(18,219)
Total Global Medical REIT Inc. stockholders' equity	615,721	444,805
Noncontrolling interest	14,504	12,955
Total equity	630,225	457,760
Total liabilities and equity	<u>\$ 1,243,306</u>	<u>\$ 1,100,906</u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**GLOBAL MEDICAL REIT INC.**  
**Condensed Consolidated Statements of Operations**  
**(unaudited and in thousands, except per share amounts)**

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2020	2021	2020
<b>Revenue</b>				
Rental revenue	\$ 29,967	\$ 25,055	\$ 85,492	\$ 68,623
Other income	16	42	101	178
Total revenue	<u>29,983</u>	<u>25,097</u>	<u>85,593</u>	<u>68,801</u>
<b>Expenses</b>				
General and administrative	3,852	4,027	12,519	7,509
Operating expenses	3,973	3,619	10,964	8,256
Management fees – related party	—	—	—	4,024
Depreciation expense	8,639	6,954	24,779	19,383
Amortization expense	3,303	2,563	9,443	6,832
Interest expense	4,830	4,864	14,887	13,616
Management internalization expense	—	12,580	—	14,005
Preacquisition expense	18	70	146	267
Total expenses	<u>24,615</u>	<u>34,677</u>	<u>72,738</u>	<u>73,892</u>
Net income (loss)	\$ 5,368	\$ (9,580)	\$ 12,855	\$ (5,091)
Less: Preferred stock dividends	(1,455)	(1,455)	(4,366)	(4,366)
Less: Net (income) loss attributable to noncontrolling interest	(224)	767	(492)	647
<b>Net income (loss) attributable to common stockholders</b>	<u>\$ 3,689</u>	<u>\$ (10,268)</u>	<u>\$ 7,997</u>	<u>\$ (8,810)</u>
Net income (loss) attributable to common stockholders per share – basic and diluted	\$ 0.06	\$ (0.22)	\$ 0.13	\$ (0.19)
Weighted average shares outstanding – basic and diluted	64,204	46,908	59,398	45,503

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**GLOBAL MEDICAL REIT INC.**  
**Condensed Consolidated Statements of Comprehensive Income (Loss)**  
**(unaudited and in thousands)**

	<u>Three Months Ended September 30,</u>		<u>Nine Months Ended September 30,</u>	
	<u>2021</u>	<u>2020</u>	<u>2021</u>	<u>2020</u>
Net income (loss)	\$ 5,368	\$ (9,580)	\$ 12,855	\$ (5,091)
Other comprehensive income (loss):				
Increase (decrease) in fair value of interest rate swap agreements	1,838	2,003	6,273	(12,977)
Total other comprehensive income (loss)	1,838	2,003	6,273	(12,977)
Comprehensive income (loss)	7,206	(7,577)	19,128	(18,068)
Less: Preferred stock dividends	(1,455)	(1,455)	(4,366)	(4,366)
Less: Comprehensive (income) loss attributable to noncontrolling interest	(329)	628	(858)	1,555
Comprehensive income (loss) attributable to common stockholders	<u>\$ 5,422</u>	<u>\$ (8,404)</u>	<u>\$ 13,904</u>	<u>\$ (20,879)</u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**GLOBAL MEDICAL REIT INC.**  
**Condensed Consolidated Statements of Equity**  
**(unaudited and in thousands, except per share amounts)**

**For the Nine Months Ended September 30, 2021:**

	Common Stock		Preferred Stock		Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Global Medical REIT Inc. Stockholders' Equity	Non-controlling Interest	Total Equity
	Shares	Amount	Shares	Amount						
Balances, December 31, 2020	49,461	\$ 49	3,105	\$ 74,959	\$ 504,789	\$ (116,773)	\$ (18,219)	\$ 444,805	\$ 12,955	\$ 457,760
Net income	—	—	—	—	—	12,363	—	12,363	492	12,855
Issuance of shares of common stock, net	14,685	15	—	—	194,498	—	—	194,513	—	194,513
LTIP Units and OP Units redeemed for common stock	62	—	—	—	919	—	—	919	(919)	—
Change in fair value of interest rate swap agreements	—	—	—	—	—	—	6,273	6,273	—	6,273
Stock-based compensation expense	—	—	—	—	—	—	—	—	4,568	4,568
Dividends to common stockholders (\$0.615 per share)	—	—	—	—	—	(38,786)	—	(38,786)	—	(38,786)
Dividends to preferred stockholders (\$1.40625 per share)	—	—	—	—	—	(4,366)	—	(4,366)	—	(4,366)
Dividends to noncontrolling interest	—	—	—	—	—	—	—	—	(2,592)	(2,592)
Balances, September 30, 2021	<u>64,208</u>	<u>\$ 64</u>	<u>3,105</u>	<u>\$ 74,959</u>	<u>\$ 700,206</u>	<u>\$ (147,562)</u>	<u>\$ (11,946)</u>	<u>\$ 615,721</u>	<u>\$ 14,504</u>	<u>\$ 630,225</u>

**For the Three Months Ended September 30, 2021:**

	Common Stock		Preferred Stock		Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Global Medical REIT Inc. Stockholders' Equity	Non-controlling Interest	Total Equity
	Shares	Amount	Shares	Amount						
Balances, June 30, 2021	64,197	\$ 64	3,105	\$ 74,959	\$ 700,038	\$ (138,088)	\$ (13,784)	\$ 623,189	\$ 14,066	\$ 637,255
Net income	—	—	—	—	—	5,144	—	5,144	224	5,368
Issuance of shares of common stock, net	—	—	—	—	—	—	—	—	—	—
LTIP Units and OP Units redeemed for common stock	11	—	—	—	168	—	—	168	(168)	—
Change in fair value of interest rate swap agreements	—	—	—	—	—	—	1,838	1,838	—	1,838
Stock-based compensation expense	—	—	—	—	—	—	—	—	1,241	1,241
Dividends to common stockholders (\$0.205 per share)	—	—	—	—	—	(13,163)	—	(13,163)	—	(13,163)
Dividends to preferred stockholders (\$0.46875 per share)	—	—	—	—	—	(1,455)	—	(1,455)	—	(1,455)
Dividends to noncontrolling interest	—	—	—	—	—	—	—	—	(859)	(859)
Balances, September 30, 2021	<u>64,208</u>	<u>\$ 64</u>	<u>3,105</u>	<u>\$ 74,959</u>	<u>\$ 700,206</u>	<u>\$ (147,562)</u>	<u>\$ (11,946)</u>	<u>\$ 615,721</u>	<u>\$ 14,504</u>	<u>\$ 630,225</u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**GLOBAL MEDICAL REIT INC.**  
**Condensed Consolidated Statements of Equity - Continued**  
**(unaudited and in thousands, except per share amounts)**

**For the Nine Months Ended September 30, 2020:**

	Common Stock		Preferred Stock		Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Global Medical REIT Inc. Stockholders' Equity	Non- controlling Interest	Total Equity
	Shares	Amount	Shares	Amount						
Balances, December 31, 2019	43,806	\$ 44	3,105	\$ 74,959	\$ 433,330	\$ (71,389)	\$ (6,674)	\$ 430,270	\$ 30,083	\$ 460,353
Net loss	—	—	—	—	—	(4,444)	—	(4,444)	(647)	(5,091)
Issuance of shares of common stock, net	3,169	3	—	—	38,234	—	—	38,237	—	38,237
LTIP Units and OP Units redeemed for common stock	1,213	1	—	—	15,550	—	—	15,551	(15,551)	—
Change in fair value of interest rate swap agreements	—	—	—	—	—	—	(12,977)	(12,977)	—	(12,977)
Stock-based compensation expense	—	—	—	—	—	—	—	—	3,391	3,391
Dividends to common stockholders (\$0.60 per share)	—	—	—	—	—	(27,744)	—	(27,744)	—	(27,744)
Dividends to preferred stockholders (\$1.40625 per share)	—	—	—	—	—	(4,366)	—	(4,366)	—	(4,366)
Dividends to noncontrolling interest	—	—	—	—	—	—	—	—	(2,596)	(2,596)
Balances, September 30, 2020	<u>48,188</u>	<u>\$ 48</u>	<u>3,105</u>	<u>\$ 74,959</u>	<u>\$ 487,114</u>	<u>\$ (107,943)</u>	<u>\$ (19,651)</u>	<u>\$ 434,527</u>	<u>\$ 14,680</u>	<u>\$ 449,207</u>

**For the Three Months Ended September 30, 2020:**

	Common Stock		Preferred Stock		Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Global Medical REIT Inc. Stockholders' Equity	Non- controlling Interest	Total Equity
	Shares	Amount	Shares	Amount						
Balances, June 30, 2020	46,252	\$ 46	3,105	\$ 74,959	\$ 462,607	\$ (88,037)	\$ (21,654)	\$ 427,921	\$ 14,788	\$ 442,709
Net loss	—	—	—	—	—	(8,813)	—	(8,813)	(767)	(9,580)
Issuance of shares of common stock, net	1,930	2	—	—	24,431	—	—	24,433	—	24,433
LTIP Units and OP Units redeemed for common stock	6	—	—	—	76	—	—	76	(76)	—
Change in fair value of interest rate swap agreements	—	—	—	—	—	—	2,003	2,003	—	2,003
Stock-based compensation expense	—	—	—	—	—	—	—	—	1,572	1,572
Dividends to common stockholders (\$0.20 per share)	—	—	—	—	—	(9,638)	—	(9,638)	—	(9,638)
Dividends to preferred stockholders (\$0.46875 per share)	—	—	—	—	—	(1,455)	—	(1,455)	—	(1,455)
Dividends to noncontrolling interest	—	—	—	—	—	—	—	—	(837)	(837)
Balances, September 30, 2020	<u>48,188</u>	<u>\$ 48</u>	<u>3,105</u>	<u>\$ 74,959</u>	<u>\$ 487,114</u>	<u>\$ (107,943)</u>	<u>\$ (19,651)</u>	<u>\$ 434,527</u>	<u>\$ 14,680</u>	<u>\$ 449,207</u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**GLOBAL MEDICAL REIT INC.**  
**Condensed Consolidated Statements of Cash Flows**  
**(unaudited and in thousands)**

	Nine Months Ended September 30,	
	2021	2020
<b>Operating activities</b>		
Net income (loss)	\$ 12,855	\$ (5,091)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:		
Depreciation expense	24,779	19,383
Amortization of acquired lease intangible assets	9,378	6,813
Amortization of above market leases, net	318	472
Amortization of debt issuance costs and other	1,468	1,030
Stock-based compensation expense	4,568	3,391
Capitalized preacquisition costs charged to expense	123	167
Reserve for uncollectible receivables	(100)	727
Other	38	45
Changes in operating assets and liabilities:		
Tenant receivables	570	(2,472)
Deferred assets	(4,150)	(4,416)
Other assets and liabilities	(1,379)	(322)
Accounts payable and accrued expenses	2,956	1,169
Security deposits	260	(780)
Accrued management fees due to related party	—	(1,727)
Net cash provided by operating activities	<u>51,684</u>	<u>18,389</u>
<b>Investing activities</b>		
Purchase of land, buildings, and other tangible and intangible assets and liabilities	(165,743)	(136,813)
Internalization - cash paid for acquisition of former advisor, net of cash acquired of \$ 559	—	(5,093)
Escrow deposits for purchase of properties	795	700
Loans (made to) repayments received from related parties	(172)	10
Capital expenditures on existing real estate investments	(1,620)	(416)
Net cash used in investing activities	<u>(166,740)</u>	<u>(141,612)</u>
<b>Financing activities</b>		
Net proceeds received from common equity offerings	194,433	38,137
Escrow deposits required by third party lenders	(1,948)	(1,034)
Proceeds from notes payable	—	14,800
Repayment of notes payable	(7,731)	(233)
Proceeds from Credit Facility	187,700	158,400
Repayment of Credit Facility	(207,200)	(51,550)
Payment of debt issuance costs	(6,177)	(1,266)
Dividends paid to common stockholders, and OP Unit and LTIP Unit holders	(38,539)	(29,588)
Dividends paid to preferred stockholders	(4,366)	(4,366)
Net cash provided by financing activities	<u>116,172</u>	<u>123,300</u>
Net increase in cash and cash equivalents and restricted cash	1,116	77
Cash and cash equivalents and restricted cash—beginning of period	10,753	7,185
Cash and cash equivalents and restricted cash—end of period	<u>\$ 11,869</u>	<u>\$ 7,262</u>
<b>Supplemental cash flow information:</b>		
Cash payments for interest	\$ 13,307	\$ 12,339
<b>Noncash financing and investing activities:</b>		
Accrued dividends payable	\$ 15,309	\$ 11,843
Interest rate swap agreements fair value change recognized in other comprehensive loss	\$ (6,273)	\$ 12,977
LTIP Units and OP Units redeemed for common stock	\$ 919	\$ 15,551
CMBS loan assumed in connection with a facility acquisition	\$ —	\$ 12,074
Accrued common stock offering costs	\$ —	\$ 169
Accrued capital expenditures included in accounts payable and accrued expenses	\$ 909	\$ 975
Recognition of lease liability related to right of use asset	\$ 511	\$ 727

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.



**GLOBAL MEDICAL REIT INC.**  
**Notes to the Unaudited Condensed Consolidated Financial Statements**  
**(in thousands, except per share amounts or as otherwise indicated)**

**Note 1 – Organization**

Global Medical REIT Inc. (the “Company”) is a Maryland corporation engaged primarily in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to strong healthcare systems and groups with leading market share. The Company holds its facilities and conducts its operations through a Delaware limited partnership subsidiary named Global Medical REIT L.P. (the “Operating Partnership”). The Company serves as the sole general partner of the Operating Partnership through a wholly owned subsidiary of the Company named Global Medical REIT GP LLC, a Delaware limited liability company. As of September 30, 2021, the Company was the 94.28% limited partner of the Operating Partnership, with an aggregate of 5.72% of the Operating Partnership owned by holders of long-term incentive plan units (“LTIP Units”) and third-party limited partners who contributed properties or services to the Operating Partnership in exchange for common limited partnership units (“OP Units”). Until July 9, 2020, the Company was externally managed and advised by its former advisor. On July 9, 2020, the Company completed its management internalization transaction, whereby the management agreement with the former advisor was terminated, the employees of the former advisor became employees of the Company and the functions previously performed by the former advisor were internalized by the Company.

**Note 2 – Summary of Significant Accounting Policies**

**Basis of presentation**

The accompanying condensed consolidated financial statements are unaudited and include the accounts of the Company, including the Operating Partnership and its wholly owned subsidiaries. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures required for annual consolidated financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, the accompanying condensed consolidated financial statements do not include all the information and footnotes required by GAAP for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2020. In the opinion of management, all adjustments of a normal and recurring nature necessary for a fair presentation of the condensed consolidated financial statements for the interim periods have been made.

**Principles of Consolidation**

The accompanying condensed consolidated financial statements include the accounts of the Company and its subsidiaries. The Company presents the portion of any equity it does not own but controls (and thus consolidates) as noncontrolling interest. Noncontrolling interest in the Company includes the LTIP Units and the OP Units held by third parties. Refer to Note 5 – “Equity” and Note 7 – “Stock-Based Compensation” for additional information regarding the OP Units and LTIP Units.

The Company classifies noncontrolling interest as a component of consolidated equity on its Condensed Consolidated Balance Sheets, separate from the Company’s total equity. The Company’s net income or loss is allocated to noncontrolling interests based on the respective ownership or voting percentage in the Operating Partnership associated with such noncontrolling interests and is removed from consolidated income or loss on the Condensed Consolidated Statements of Operations in order to derive net income or loss attributable to common stockholders. The noncontrolling ownership percentage is calculated by dividing the aggregate number of LTIP Units and OP Units by the total number of units and shares outstanding. Any future issuances of additional LTIP Units or OP Units would change the noncontrolling ownership interest.

**Use of Estimates**

The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Actual results could differ from those estimates.

## Investment in Real Estate

The Company determines when an acquisition meets the definition of a business or alternatively should be accounted for as an asset acquisition in accordance with Accounting Standard Codification (“ASC”) Topic 805 “Business Combinations” (“ASC Topic 805”), which requires that, when substantially all of the fair value of an acquisition is concentrated in a single identifiable asset or a group of similar identifiable assets, the asset or group of similar identifiable assets does not meet the definition of a business and therefore is required to be accounted for as an asset acquisition. Transaction costs are capitalized for asset acquisitions and expensed as incurred for business combinations. All our facility acquisitions for the nine months ended September 30, 2021 and 2020 have been accounted for as asset acquisitions because substantially all the fair value of the gross assets the Company acquired were concentrated in a single asset or group of similar identifiable assets.

For asset acquisitions that are “owner occupied” (meaning that the seller either is the tenant or controls the tenant), the purchase price, including capitalized acquisition costs, will be allocated to land and building based on their relative fair values with no value allocated to intangible assets or liabilities. For asset acquisitions that are not “owner occupied,” the Company will allocate the purchase price to tangible assets and any intangible assets acquired or liabilities assumed based on their relative fair values. Fair value is determined based upon the guidance of ASC Topic 820, “Fair Value Measurements and Disclosures,” and generally are determined using Level 2 inputs, such as rent comparables, sales comparables, and broker indications. Although Level 3 inputs are utilized, they are minor in comparison to the Level 2 data used for the primary assumptions. The determination of fair value involves the use of significant judgment and estimates. We make estimates to determine the fair value of the tangible and intangible assets acquired and liabilities assumed using information obtained from multiple sources, including preacquisition due diligence, and we routinely utilize the assistance of a third-party appraiser.

## Revenue Recognition

The Company’s operations primarily consist of rental revenue earned from tenants under leasing arrangements which provide for minimum rent and escalations. The leases have been accounted for as operating leases. For operating leases with contingent rental escalators, revenue is recorded based on the contractual cash rental payments due during the period. Revenue from leases with fixed annual rental escalators are recognized on a straight-line basis over the initial lease term, subject to a collectability assessment, with the difference between the contractual rental receipts and the straight-line amounts recorded as a “deferred rent receivable.” Additionally, the Company recognizes “expense recoveries” revenue, which represents revenue recognized related to tenant reimbursement of real estate taxes, insurance, and certain other operating expenses (“tenant reimbursements”). The Company recognizes these reimbursements and related expenses on a gross basis in its Condensed Consolidated Statements of Operations.

## Cash and Cash Equivalents and Restricted Cash

The Company considers all demand deposits, cashier’s checks, money market accounts, and certificates of deposit with a maturity of three months or less to be cash equivalents. Amounts included in restricted cash represent (1) certain security deposits received from tenants at the inception of their leases; (2) cash required to be held by a third-party lender as a reserve for debt service; and (3) funds held by the Company related to tenant reimbursements. The following table provides a reconciliation of the Company’s cash and cash equivalents and restricted cash that sums to the total of those amounts at the end of the periods presented on the Company’s accompanying Condensed Consolidated Statements of Cash Flows:

	As of September 30,	
	2021	2020
Cash and cash equivalents	\$ 6,030	\$ 2,052
Restricted cash	5,839	5,210
Total cash and cash equivalents and restricted cash	<u>\$ 11,869</u>	<u>\$ 7,262</u>

## Tenant Receivables, Net

The tenant receivable balance as of September 30, 2021 and December 31, 2020 was \$5,126 and \$5,596, respectively. The balance as of September 30, 2021 consisted of \$1,085 in funds owed from the Company’s tenants for rent that the Company had earned but had not yet received, \$1,168 of loans that were made to two of the Company’s tenants, and \$2,873 of tenant reimbursements. The balance as of December 31, 2020 consisted of \$1,066 in funds owed from the Company’s tenants for rent that the Company had earned but had not yet received, \$1,200 of loans that were made to two of the Company’s tenants, and \$3,330 of tenant reimbursements.

Receivables arising from operating leases are accounted for in accordance with ASC Topic 842 “Leases” (“ASC Topic 842”). The Company assesses the likelihood of losses resulting from tenant defaults, or the inability of tenants to make contractual rent and tenant recovery payments at each reporting date. The Company also monitors the liquidity and creditworthiness of its tenants and operators on a continuous basis. If the likelihood of a tenant paying its lease payments is determined to no longer be probable, all tenant receivables, including deferred rent, are written off against revenue and any future revenue for that tenant is recognized only upon receipt of cash. In addition, as of September 30, 2021, the Company had a portfolio level reserve of \$350 on those leases that were probable of collection to ensure that the tenant lease receivables were not overstated.

#### **Escrow Deposits**

The escrow balance as of September 30, 2021 and December 31, 2020 was \$5,970 and \$4,817, respectively. Escrow deposits include funds held in escrow to be used for the acquisition of properties in the future and for the payment of taxes, insurance, and other amounts as stipulated by the Company’s Cantor Loan, as hereinafter defined.

#### **Deferred Assets**

The deferred assets balance as of September 30, 2021 and December 31, 2020 was \$24,422 and \$20,272, respectively. The balance as of September 30, 2021 consisted of \$24,339 in deferred rent receivables resulting from the recognition of revenue from leases with fixed annual rental escalations on a straight-line basis and \$83 of other deferred costs. The balance as of December 31, 2020 consisted of \$20,192 in deferred rent receivables resulting from the recognition of revenue from leases with fixed annual rental escalations on a straight-line basis and \$80 of other deferred costs.

#### **Other Assets**

The other assets balance as of September 30, 2021 and December 31, 2020 was \$8,297 and \$5,019, respectively. The balance as of September 30, 2021 consisted of \$3,887 for right of use assets, \$1,505 in preacquisition and other capitalized costs related to our properties, \$2,626 in prepaid assets, and \$279 for net capitalized software costs and miscellaneous assets. The balance as of December 31, 2020 consisted of \$3,598 for right of use assets, \$484 in capitalized preacquisition costs, \$588 in prepaid assets, and \$349 for net capitalized software costs and miscellaneous assets. Refer to Note 8 – “Leases” for additional details on right of use assets.

#### **Derivative Instruments - Interest Rate Swaps**

As of September 30, 2021 and December 31, 2020, the Company's net liability balance related to interest rate swap derivative instruments that were designated as cash flow hedges of interest rate risk was \$11,851 and \$18,086, respectively. In accordance with the Company’s risk management strategy, the purpose of the interest rate swaps is to manage interest rate risk for certain of the Company’s variable-rate debt. The interest rate swaps involve the Company’s receipt of variable-rate amounts from four counterparties in exchange for the Company making fixed-rate payments over the life of the agreements. The Company accounts for derivative instruments in accordance with the provisions of ASC Topic 815, “Derivatives and Hedging.” Refer to Note 4 – “Credit Facility, Notes Payable and Derivative Instruments” for additional details.

#### **Management Internalization Expense**

As discussed in Note 1 – “Organization,” on July 9, 2020, the Company completed its management internalization transaction. The total amount of consideration for the transaction, after a working capital adjustment, was \$17,746. The portion of the consideration paid for the transaction that was attributed to the settlement of a preexisting contractual relationship (the Management Agreement (as hereafter defined)) of \$12,094 was recognized as “Management Internalization Expense” in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and the \$5,903 of excess consideration paid over the fair value of underlying identifiable net liabilities of the business acquired of \$251 was recorded as “Goodwill” in the accompanying Condensed Consolidated Balance Sheets. The Company also incurred \$486 and \$1,911 of expense related to the management internalization for the three and nine months ended September 30, 2020, respectively, which are also included in the “Management Internalization Expense” line item for the three and nine months ended September 30, 2020.

## **Goodwill**

As of September 30, 2021 and December 31, 2020, the Company's goodwill balance was \$5,903. Goodwill represents the excess of consideration paid over the fair value of underlying identifiable net assets of businesses acquired. The Company's goodwill balance was derived from its management internalization transaction. Goodwill has an indefinite life and is not amortized, but is tested for impairment on an annual basis, or more frequently if events or changes in circumstances indicate that the asset might be impaired. The Company's policy is to perform its annual goodwill impairment evaluation as of the first day of the fourth quarter of its fiscal year. The Company has one reporting unit.

## **Sales of Real Estate**

The Company classifies a property as held for sale when the criteria are met, in accordance with GAAP. At that time, the Company presents the assets and obligations associated with the real estate held for sale separately in its Condensed Consolidated Balance Sheets, and ceases recording depreciation and amortization expense related to that asset. Real estate held for sale is reported at the lower of its carrying amount or its estimated fair value less estimated costs to sell.

Upon the disposition of a property, the Company recognizes a gain or loss at a point in time when the Company determines control of the underlying asset has been transferred to the buyer. The Company's performance obligation is generally satisfied at the closing of the transaction. Any continuing involvement is analyzed as a separate performance obligation in the contract, and a portion of the sales price is allocated to each performance obligation. There is significant judgment applied to estimate the amount of any variable consideration identified within the sales price and assess its probability of occurrence based on current market information, historical transactions, and forecasted information that is reasonably available.

For sales of real estate (or assets classified as held for sale), the Company evaluates whether the disposition is a strategic shift that will have a major effect on the Company's operations and financial results. If a disposition represents a strategic shift that will have a major effect on the Company's operations and financial results, it will be classified as discontinued operations in the Company's condensed consolidated financial statements for all periods presented.

## **Recent Accounting Pronouncements**

### ***Reference Rate Reform***

Accounting Standards Update ("ASU") 2020-04, Reference Rate Reform (Topic 848) ("ASU 2020-04") contains practical expedients for reference rate reform-related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. As of September 30, 2021, the Company had previously elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.

## **Note 3 – Property Portfolio**

### **Summary of Properties Acquired During the Nine Months Ended September 30, 2021**

During the nine months ended September 30, 2021 the Company completed 16 acquisitions. For each acquisition, substantially all of the fair value was concentrated in a single identifiable asset or group of similar identifiable assets and, therefore, each acquisition represents an asset acquisition. Accordingly, transaction costs for these acquisitions were capitalized.

[Table of Contents](#)

A rollforward of the gross investment in land, building, improvements, and acquired lease intangible assets as of September 30, 2021 resulting from these acquisitions is as follows:

	Land	Building	Site Improvements	Tenant Improvements	Acquired Lease Intangible Assets	Gross Investment in Real Estate
Balances as of December 31, 2020	\$ 128,857	\$ 851,427	\$ 15,183	\$ 49,204	\$ 98,234	\$ 1,142,905
Facility Acquired – Date Acquired:						
El Paso – 1/12/21	899	7,549	71	160	1,338	10,017
Syracuse – 1/15/21	616	4,745	128	136	772	6,397
West El Paso – 1/15/21	851	7,160	144	567	856	9,578
Fort Worth – 3/9/21	1,817	13,020	143	395	2,069	17,444
Port St. Lucie – 4/6/21	590	3,583	70	185	359	4,787
Cape Coral and Fort Myers – 4/13/21	5,623	20,155	480	1,132	4,311	31,701
Dallas – 4/16/21	3,101	2,593	63	469	493	6,719
East Grand Forks – 4/19/21	845	6,248	278	815	2,092	10,278
Coos Bay – 4/21/21	861	5,095	56	50	410	6,472
Caledonia – 6/2/21	582	2,669	66	96	497	3,910
Tallahassee – 6/2/21	782	6,720	137	387	1,218	9,244
Forsyth – 7/28/21	1,554	9,627	348	456	7,439	19,424
North Charleston – 7/29/21	927	4,248	106	801	1,098	7,180
Munster – 9/15/21	780	4,451	161	391	953	6,736
Hialeah – 9/30/21	—	9,633	264	716	1,231	11,844
Athens – 9/30/21	564	4,106	58	63	548	5,339
Capitalized costs <sup>(1)</sup>	—	1,140	261	133	—	1,534
Total Additions:	20,392	112,742	2,834	6,952	25,684	168,604
Balances as of September 30, 2021	\$ 149,249	\$ 964,169	\$ 18,017	\$ 56,156	\$ 123,918	\$ 1,311,509

<sup>(1)</sup> Represents capital projects that were completed and placed in service during the nine months ended September 30, 2021 related to the Company's existing facilities.

Depreciation expense was \$8,639 and \$24,779 for the three and nine months ended September 30, 2021, respectively, and \$6,954 and \$19,383 for the three and nine months ended September 30, 2020, respectively.

As of September 30, 2021, the Company had aggregate capital improvement commitments and obligations to improve, expand, and maintain the Company's existing facilities of approximately \$28,900. Many of these amounts are subject to contingencies that make it difficult to predict when they will be utilized, if at all. In accordance with the terms of the Company's leases, capital improvement obligations in the next twelve months could total up to approximately \$23,900.

The following is a summary of the acquisitions completed during the nine months ended September 30, 2021.

**El Paso Facility**

On January 12, 2021, the Company purchased a medical office building located in El Paso, Texas (the "El Paso Facility") for a purchase price of approximately \$10.0 million. Upon closing the Company assumed three existing leases at the El Paso Facility (the "El Paso Leases"). At acquisition, the El Paso Leases had a weighted-average remaining term of approximately four years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$ 970
Building and tenant improvements	7,709
In-place leases	750
Above-market lease intangibles	383
Leasing costs	205
Total purchase price	\$ 10,017

**Syracuse Facility**

On January 15, 2021, the Company purchased a medical office building located in Syracuse, New York (the “Syracuse Facility”) for a purchase price of approximately \$6.2 million. Upon closing the Company assumed two existing leases at the Syracuse Facility (the “Syracuse Leases”). At acquisition, the Syracuse Leases had a weighted-average remaining term of approximately eight years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	744
Building and tenant improvements		4,881
In-place leases		434
Leasing costs		338
Below-market lease intangibles		(207)
Total purchase price	\$	<u>6,190</u>

**West El Paso Facilities**

On January 15, 2021, the Company purchased two medical office buildings and an ambulatory surgical center located in El Paso, Texas (the “West El Paso Facilities”) for a total purchase price of approximately \$9.6 million. Upon closing the Company entered into two new leases at the medical office buildings with 12-year terms and assumed the existing lease at the ambulatory surgery center, which, at acquisition, had a remaining term of seven years. All three leases have tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	995
Building and tenant improvements		7,727
In-place leases		432
Leasing costs		424
Total purchase price	\$	<u>9,578</u>

**Fort Worth Facility**

On March 9, 2021, the Company purchased an inpatient psychiatric hospital located in Fort Worth, Texas (the “Fort Worth Facility”) for a purchase price of approximately \$17.4 million. Upon closing the Company assumed the existing lease at the Fort Worth Facility (the “Fort Worth Lease”). At acquisition, the Fort Worth Lease had a remaining term of approximately eight years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	1,960
Building and tenant improvements		13,415
In-place leases		1,339
Leasing costs		730
Total purchase price	\$	<u>17,444</u>

**Port St. Lucie Facility**

On April 6, 2021, the Company purchased a medical office building with an ambulatory surgical center located in Port St. Lucie, Florida (the “Port St. Lucie Facility”) for a purchase price of approximately \$4.8 million. Upon closing the Company assumed two existing leases at the Port St. Lucie Facility (the “Port St. Lucie Leases”). At acquisition, the Port St. Lucie Leases had a weighted-average remaining term of approximately six years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	660
Building and tenant improvements		3,768
In-place leases		245
Leasing costs		114
Total purchase price	\$	<u>4,787</u>

**Cape Coral and Fort Myers Facilities**

On April 13, 2021, the Company purchased a six-property medical office portfolio located in Cape Coral, Florida and Fort Myers, Florida (the “Cape Coral and Fort Myers Facilities”) for a total purchase price of approximately \$31.7 million. Upon closing the Company assumed six existing leases at the Cape Coral and Fort Myers Facilities (the “Cape Coral and Fort Myers Leases”). At acquisition, the Cape Coral and Fort Myers Leases had a weighted-average remaining term of approximately five years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	6,103
Building and tenant improvements		21,287
In-place leases		2,112
Above-market lease intangibles		1,418
Leasing costs		781
Total purchase price	\$	<u>31,701</u>

**Dallas Facility**

On April 16, 2021, the Company purchased a medical office building with a surgery center located in Dallas, Texas (the “Dallas Facility”) for a purchase price of approximately \$6.4 million. Upon closing the Company assumed two existing leases at the Dallas Facility (the “Dallas Leases”). At acquisition, the Dallas Leases had a weighted-average remaining term of approximately seven years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	3,164
Building and tenant improvements		3,062
In-place leases		275
Leasing costs		218
Below-market lease intangibles		(295)
Total purchase price	\$	<u>6,424</u>

**East Grand Forks Facilities**

On April 19, 2021, the Company purchased two medical office buildings located in East Grand Forks, Minnesota (the “East Grand Forks Facilities”) for a total purchase price of approximately \$9.7 million. Upon closing the Company assumed two existing leases at the East Grand Forks Facilities (the “East Grand Forks Leases”). At acquisition, the East Grand Forks Leases had a weighted-average remaining term of approximately four years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	1,123
Building and tenant improvements		7,063
In-place leases		1,839
Leasing costs		253
Below-market lease intangibles		(554)
Total purchase price	\$	<u>9,724</u>

**Coos Bay Facility**

On April 21, 2021, the Company purchased a medical office building in Coos Bay, Oregon (the “Coos Bay Facility”) for a purchase price of approximately \$6.5 million. Upon closing the Company assumed the existing lease at the Coos Bay Facility (the “Coos

Bay Lease”). At acquisition, the Coos Bay Lease had a remaining lease term of approximately three years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	917
Building and tenant improvements		5,145
In-place leases		316
Leasing costs		94
Total purchase price	\$	<u>6,472</u>

#### Caledonia Facility

On June 2, 2021, the Company purchased a medical office building in Caledonia, Michigan (the “Caledonia Facility”) for a purchase price of approximately \$3.9 million. Upon closing the Company assumed four existing leases at the Caledonia Facility (the “Caledonia Leases”). At acquisition, the Caledonia Leases had a remaining lease term of approximately four years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	648
Building and tenant improvements		2,765
In-place leases		410
Leasing costs		87
Below-market lease intangibles		(47)
Total purchase price	\$	<u>3,863</u>

#### Tallahassee Facility

On June 2, 2021, the Company purchased a medical office building in Tallahassee, Florida (the “Tallahassee Facility”) for a purchase price of approximately \$9.2 million. Upon closing the Company assumed two existing leases at the Tallahassee Facility (the “Tallahassee Leases”). At acquisition, the Tallahassee Leases had a remaining lease term of approximately nine years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	919
Building and tenant improvements		7,107
In-place leases		708
Leasing costs		510
Total purchase price	\$	<u>9,244</u>

#### Forsyth Facilities

On July 28, 2021, the Company purchased two medical office buildings located in Forsyth, Illinois (the “Forsyth Facilities”) for a total purchase price of approximately \$19.3 million. Upon closing the Company assumed six existing leases at the Forsyth Facilities (the “Forsyth Leases”). At acquisition, the Forsyth Leases had a weighted-average remaining term of approximately 10 years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	1,902
Building and tenant improvements		10,083
In-place leases		1,456
Above-market lease intangibles		4,946
Leasing costs		1,037
Below-market lease intangibles		(164)
Total purchase price	\$	<u>19,260</u>

#### North Charleston Facility

On July 29, 2021, the Company purchased a medical office building in North Charleston, South Carolina (the “North Charleston Facility”) for a purchase price of approximately \$7.2 million. Upon closing the Company entered into a new lease with the existing



tenant at the North Charleston Facility (the “North Charleston Lease”). The North Charleston Lease has a term of 5 years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	1,033
Building and tenant improvements		5,049
In-place leases		534
Leasing costs		564
Total purchase price	\$	<u>7,180</u>

#### Munster Facility

On September 15, 2021, the Company purchased certain condominium units within a medical office building in Munster, Indiana (the “Munster Facility”) for a purchase price of approximately \$6.7 million. Upon closing the Company assumed five leases with five tenants and entered into three new leases with three existing tenants at the Munster Facility (the “Munster Leases”). At acquisition, the Munster Leases had a weighted-average remaining lease term of approximately seven years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	941
Building and tenant improvements		4,842
In-place leases		385
Above-market lease intangibles		292
Leasing costs		276
Below-market lease intangibles		(57)
Total purchase price	\$	<u>6,679</u>

#### Hialeah Facility

On September 30, 2021, the Company purchased a medical office building located in Hialeah, Florida (the “Hialeah Facility”) and the seller’s interest, as ground lessee, in an existing ground lease, for a total purchase price of \$11.7 million. At acquisition, the ground lease had a remaining term of approximately 39 years. Upon closing the Company assumed 42 existing leases at the Hialeah Facility (the “Hialeah Leases”). At acquisition, the Hialeah Leases had a weighted-average remaining term of approximately 2 years, exclusive of tenant renewal options; however, due to the number of leases at the Hialeah Facility, the weighted-average remaining lease term is not comparative to the weighted-average remaining lease terms of the Company’s single-tenant properties. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	264
Building and tenant improvements		10,349
In-place leases		931
Leasing costs		300
Below-market lease intangibles		(150)
Total purchase price	\$	<u>11,694</u>

#### Athens Facility

On September 30, 2021, the Company purchased a medical office building in Athens, Georgia (the “Athens Facility”) for a purchase price of approximately \$5.3 million. Upon closing the Company assumed the existing lease at the Athens Facility (the “Athens Lease”). At acquisition, the Athens Lease had a remaining lease term of approximately three years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	622
Building and tenant improvements		4,169
In-place leases		472
Leasing costs		76
Total purchase price	\$	<u>5,339</u>

**Summary of Properties Acquired During the Year Ended December 31, 2020**

During the year ended December 31, 2020 the Company completed 18 acquisitions. For each acquisition, substantially all of the fair value was concentrated in a single identifiable asset or group of similar identifiable assets and, therefore, each acquisition represents an asset acquisition. Accordingly, transaction costs for these acquisitions were capitalized.

A rollforward of the gross investment in land, building, improvements, and acquired lease intangible assets as of December 31, 2020 resulting from these acquisitions is as follows:

	<u>Land</u>	<u>Building</u>	<u>Site Improvements</u>	<u>Tenant Improvements</u>	<u>Acquired Lease Intangible Assets</u>	<u>Gross Investment in Real Estate</u>
Balances as of December 31, 2019	\$ 95,381	\$ 693,533	\$ 9,912	\$ 33,909	\$ 72,794	\$ 905,529
Facility Acquired – Date Acquired:						
High Point – 2/13/20	1,749	20,367	440	869	1,656	25,081
Clinton – 2/27/20	664	6,551	342	1,578	2,484	11,619
West Allis – 3/4/20	974	7,687	137	98	461	9,357
Grand Rapids – 3/20/20	2,951	17,341	470	450	1,582	22,794
Dumfries – 4/27/20	2,597	10,047	289	4,815	4,292	22,040
Centerville – 7/16/20	—	4,202	160	208	501	5,071
Fairfax – 7/17/20	6,731	6,642	381	2,979	3,012	19,745
Rosedale – 7/31/20	2,856	16,204	567	1,443	2,821	23,891
Lancaster – 9/18/20	696	4,269	110	116	1,114	6,305
Winston-Salem – 9/30/20	1,524	6,407	254	307	748	9,240
Decatur and Jackson – 10/20/20	2,237	7,140	284	296	955	10,912
Sheboygan and Plymouth – 10/27/20	1,088	11,212	253	225	1,046	13,824
Spring Hill and Hudson – 11/18/20	3,473	12,520	420	435	1,370	18,218
Cape Girardeau – 11/23/20	1,150	4,601	73	264	1,262	7,350
Yuma – 12/1/20	1,041	4,715	309	274	640	6,979
Las Vegas – 12/14/20	311	6,813	—	—	—	7,124
Pensacola – 12/29/20	1,786	5,742	332	411	781	9,052
Venice – 12/30/20	1,648	4,204	247	333	543	6,975
Capitalized costs <sup>(1)</sup>	—	1,230	203	194	172	1,799
Total Additions:	33,476	157,894	5,271	15,295	25,440	237,376
Balances as of December 31, 2020	\$ 128,857	\$ 851,427	\$ 15,183	\$ 49,204	\$ 98,234	\$ 1,142,905

<sup>(1)</sup> Represents capital projects that were completed and placed in service during the year ended December 31, 2020 related to the Company's existing facilities.

The following is a summary of the acquisitions completed during the year ended December 31, 2020.

**High Point Facility**

On February 13, 2020, the Company purchased a medical office building located in High Point, North Carolina (the "High Point Facility") for a purchase price of approximately \$25.1 million. Upon closing, the Company assumed the existing lease of the High Point Facility with Wake Forest Health Network, LLC, as tenant. At acquisition, the lease had approximately three years remaining in the current term, exclusive of a tenant renewal option. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$ 2,189
Building and tenant improvements	21,236
In-place leases	1,207
Leasing costs	449
Total purchase price	\$ 25,081

**Clinton Facility**

On February 27, 2020, the Company purchased a medical office building located in Clinton, Iowa (the “Clinton Facility”) for a purchase price of approximately \$11.6 million. Upon closing, the Company assumed the existing lease of the Clinton Facility with MercyOne Clinton Medical Center, as tenant. At acquisition, the lease had approximately four years remaining in the initial term, exclusive of a tenant renewal option. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	1,006
Building and tenant improvements		8,129
In-place leases		2,115
Leasing costs		369
Total purchase price	\$	<u>11,619</u>

**West Allis Facility**

On March 4, 2020, the Company purchased a medical office building located in West Allis, Wisconsin (the “West Allis Facility”) for a purchase price of approximately \$9.1 million. Upon closing, the Company assumed the existing lease of the West Allis Facility with Ascension Columbia St. Mary’s Hospital Milwaukee, as tenant. At acquisition, the lease had approximately four years remaining in the initial term, exclusive of renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	1,111
Building and tenant improvements		7,785
In-place leases		263
Leasing costs		198
Below-market lease intangibles		(264)
Total purchase price	\$	<u>9,093</u>

**Grand Rapids Facilities**

On March 20, 2020, the Company purchased a four-building medical office portfolio located in the greater Grand Rapids, Michigan area (the “Grand Rapids Facilities”) for a total purchase price of approximately \$22.7 million. Upon closing, the Company assumed 11 existing leases at the Grand Rapids Facilities (the “Grand Rapids Leases”). At acquisition, the Grand Rapids Leases had a weighted-average remaining term of five years, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	3,417
Building and tenant improvements		17,791
In-place leases		761
Above-market lease intangibles		685
Leasing costs		136
Below-market lease intangibles		(125)
Total purchase price	\$	<u>22,665</u>

**Dumfries Facility**

On April 27, 2020, the Company purchased a medical office building located in Dumfries, Virginia (the “Dumfries Facility”) for a purchase price of approximately \$19.6 million. Upon closing, the Company assumed the existing lease of the Dumfries Facility with Spectrum Healthcare Resources, Inc., as tenant. At acquisition, the lease had approximately nine and a half years left in the initial term, exclusive of tenant renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	2,886
Building and tenant improvements		14,862
In-place leases		3,255
Leasing costs		1,037
Below-market lease intangibles		(2,419)
Total purchase price	\$	<u>19,621</u>

In connection with this acquisition, the Company assumed an existing \$12.1 million commercial mortgage-backed securities (“CMBS”) loan with an interest rate of 4.68% and a term of four years.

**Centerville Facility**

On July 16, 2020, the Company purchased a medical office building located in Centerville, Iowa (the “Centerville Facility”) and the seller’s interest, as ground lessee, in an existing ground lease, for a purchase price of approximately \$5.1 million. At acquisition, the ground lease had a remaining term of approximately 49 years. Upon closing, the Company assumed the existing lease of the Centerville Facility with Mercy Medical Center-Centerville One St. Joseph Drive, as tenant. At acquisition, the lease had approximately 10.5 years remaining in the initial term, exclusive of renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	160
Building and tenant improvements		4,410
In-place leases		216
Leasing costs		285
Total purchase price	\$	<u>5,071</u>

**Fairfax Facility**

On July 17, 2020, the Company purchased a medical office building located in Fairfax, Virginia (the “Fairfax Facility”) for a purchase price of approximately \$17.9 million. Upon closing, the Company assumed the existing lease of the Fairfax Facility with Spectrum Healthcare Resources, Inc., as tenant. At acquisition, the lease had approximately 9.1 years remaining in the initial term, exclusive of renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	7,112
Building and tenant improvements		9,621
In-place leases		2,314
Leasing costs		698
Below-market lease intangibles		(1,866)
Total purchase price	\$	<u>17,879</u>

**Rosedale Facilities**

On July 31, 2020, the Company purchased certain condominium units within a medical office building and a medical office building, both located in Rosedale, Maryland (the “Rosedale Facilities”) for a total purchase price of approximately \$23.1 million. Upon closing, the Company assumed eight leases with six tenants at the Rosedale Facilities (the “Rosedale Leases”). At acquisition, the

Rosedale Leases had a weighted-average remaining lease term of approximately 6.6 years, exclusive of renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	3,423
Building and tenant improvements		17,647
In-place leases		1,063
Leasing costs		892
Above-market lease intangibles		866
Below-market lease intangibles		(785)
Total purchase price	\$	<u>23,106</u>

In connection with this acquisition, the Company entered into a loan with FVCbank in the amount of \$14.8 million with an annual interest rate of 3.85% and a term of five years.

#### Lancaster Facility

On September 18, 2020, the Company purchased a medical office building located in Lancaster, Texas (the "Lancaster Facility") for a purchase price of approximately \$6.3 million. Upon closing, the Company assumed the existing lease at the Lancaster Facility with Biomat USA, Inc., as tenant. At acquisition, the lease had approximately eight and a half years left in the initial term, exclusive of a tenant renewal option. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	806
Building and tenant improvements		4,385
In-place leases		244
Leasing costs		283
Above-market lease intangibles		587
Total purchase price	\$	<u>6,305</u>

#### Winston-Salem Facility

On September 30, 2020, the Company purchased a medical office building located in Winston-Salem, North Carolina (the "Winston-Salem Facility") for a total purchase price of approximately \$8.5 million. Upon closing, the Company assumed five existing leases at the Winston-Salem Facility (the "Winston-Salem Leases"). At acquisition, the Winston-Salem Leases had a weighted-average remaining term of approximately four years, exclusive of a tenant renewal option. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	1,778
Building and tenant improvements		6,714
In-place leases		581
Leasing costs		167
Below-market lease intangibles		(725)
Total purchase price	\$	<u>8,515</u>

#### Decatur and Jackson Facilities

On October 20, 2020, the Company purchased two medical office buildings, one located in Decatur, Georgia, and one located in Jackson, Tennessee (the "Decatur and Jackson Facilities") for a total purchase price of approximately \$10.9 million. Upon closing, the Company assumed six leases with five tenants at the Decatur and Jackson Facilities (the "Decatur and Jackson Leases"). At acquisition, the Decatur and Jackson Leases had a weighted-average remaining lease term of approximately six years, exclusive of renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	2,521
Building and tenant improvements		7,436
In-place leases		556
Leasing costs		264
Above-market lease intangibles		135
Below-market lease intangibles		(27)
Total purchase price	\$	<u>10,885</u>

#### Sheboygan and Plymouth Facilities

On October 27, 2020, the Company purchased two medical office buildings, one located in Sheboygan, Wisconsin, and one located in Plymouth, Wisconsin (the “Sheboygan and Plymouth Facilities”) for a total purchase price of approximately \$13.8 million. Upon closing, the Company assumed three leases with two tenants at the Sheboygan and Plymouth Facilities (the “Sheboygan and Plymouth Leases”). At acquisition, the Sheboygan and Plymouth Leases had a weighted-average remaining lease term of approximately five years, exclusive of renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	1,341
Building and tenant improvements		11,437
In-place leases		756
Leasing costs		290
Total purchase price	\$	<u>13,824</u>

#### Spring Hill and Hudson Facilities

On November 18, 2020, the Company purchased three medical office buildings, two located in Spring Hill, Florida, and one located in Hudson, Florida (the “Spring Hill and Hudson Facilities”) for a total purchase price of approximately \$18.2 million. Upon closing, the Company assumed the three existing leases at the Spring Hill and Hudson Facilities with Florida Cancer Specialists & Research Institute LLC, as tenant. At acquisition, each lease had approximately eight years left in the initial term, exclusive of renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	3,893
Building and tenant improvements		12,955
In-place leases		831
Leasing costs		539
Total purchase price	\$	<u>18,218</u>

#### Cape Girardeau Facility

On November 23, 2020, the Company purchased an ambulatory surgery center located in Cape Girardeau, Missouri (the “Cape Girardeau Facility”) for a total purchase price of approximately \$7.4 million. Upon closing, the Company assumed the existing lease at the Cape Girardeau Facility with Physicians Alliance, L.C., as tenant. At acquisition, the lease had a remaining term of approximately six years, exclusive of renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	1,223
Building and tenant improvements		4,865
In-place leases		687
Leasing costs		188
Above-market lease intangibles		387
Total purchase price	\$	<u>7,350</u>

**Yuma Facilities**

On December 1, 2020, the Company purchased two medical office buildings located in Yuma, Arizona (the “Yuma Facilities”) for a total purchase price of approximately \$7.0 million. Upon closing, the Company assumed the two existing leases at the Yuma Facilities with Yuma Regional Medical Center, as tenant. At acquisition, the leases had a weighted-average remaining term of approximately four years, exclusive of a renewal option. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	1,350
Building and tenant improvements		4,989
In-place leases		439
Leasing costs		136
Above-market lease intangibles		65
Total purchase price	\$	<u>6,979</u>

**Las Vegas Facilities**

On December 14, 2020, the Company purchased two medical office buildings located in Las Vegas, Nevada (the “Las Vegas Facilities”) for a total purchase price of approximately \$7.1 million. Upon closing, the Company entered into new leases with two existing tenants at the Las Vegas Facilities (the “Las Vegas Leases”). The Las Vegas Leases have a term of 12 years, exclusive of renewal options. The following table presents the details of the tangible assets acquired:

Land and site improvements	\$	311
Building and tenant improvements		6,813
Total purchase price	\$	<u>7,124</u>

**Pensacola Facilities**

On December 29, 2020, the Company purchased three medical office buildings located in Pensacola, Florida (the “Pensacola Facilities”) for a total purchase price of approximately \$9.1 million. Upon closing, the Company assumed the three existing leases with two tenants at the Pensacola Facilities (the “Pensacola Leases”). At acquisition, the Pensacola Leases had a weighted-average remaining lease term of approximately nine years, exclusive of renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	2,118
Building and tenant improvements		6,153
In-place leases		456
Leasing costs		325
Total purchase price	\$	<u>9,052</u>

**Venice Facilities**

On December 30, 2020, the Company purchased two medical office buildings located in Venice, Florida (the “Venice Facilities”) for a total purchase price of approximately \$7.0 million. Upon closing, the Company assumed the two existing leases at the Venice Facilities with Gulf Coast HMA Physician Management, LLC, as tenant. At acquisition, each lease had approximately five and a half years left in initial term, with no renewal options. The following table presents the details of the tangible and intangible assets acquired and liabilities assumed:

Land and site improvements	\$	1,895
Building and tenant improvements		4,537
In-place leases		387
Leasing costs		156
Total purchase price	\$	<u>6,975</u>

**Lease Intangible Assets and Liabilities**

The following is a summary of the carrying amount of lease intangible assets and liabilities as of the dates presented:

	As of September 30, 2021		
	Cost	Accumulated Amortization	Net
<b>Assets</b>			
In-place leases	\$ 67,968	\$ (21,131)	\$ 46,837
Above market leases	22,013	(5,704)	16,309
Leasing costs	33,937	(9,123)	24,814
	<u>\$ 123,918</u>	<u>\$ (35,958)</u>	<u>\$ 87,960</u>
<b>Liability</b>			
Below market leases	\$ 11,546	\$ (3,213)	\$ 8,333
	As of December 31, 2020		
	Cost	Accumulated Amortization	Net
<b>Assets</b>			
In-place leases	\$ 55,561	\$ (14,592)	\$ 40,969
Above market leases	14,972	(4,023)	10,949
Leasing costs	27,701	(6,284)	21,417
	<u>\$ 98,234</u>	<u>\$ (24,899)</u>	<u>\$ 73,335</u>
<b>Liability</b>			
Below market leases	\$ 10,072	\$ (1,850)	\$ 8,222

The following is a summary of the acquired lease intangible amortization:

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2021	2020	2021	2020
Amortization expense related to in-place leases	\$ 2,281	\$ 1,800	\$ 6,539	\$ 4,796
Amortization expense related to leasing costs	\$ 1,000	\$ 744	\$ 2,839	\$ 2,017
Decrease in rental revenue related to above market leases	\$ 648	\$ 421	\$ 1,681	\$ 1,199
Increase in rental revenue related to below market leases	\$ 475	\$ 352	\$ 1,363	\$ 727

As of September 30, 2021, scheduled future aggregate net amortization of the acquired lease intangible assets and liabilities for each year ended December 31 is listed below:

	Net Decrease in Revenue	Net Increase in Expenses
2021 (three months remaining)	\$ (204)	\$ 3,510
2022	(830)	13,893
2023	(864)	12,939
2024	(708)	10,875
2025	(1,074)	7,579
Thereafter	(4,296)	22,855
Total	<u>\$ (7,976)</u>	<u>\$ 71,651</u>

As of September 30, 2021, the weighted average amortization periods for asset lease intangibles and liability lease intangibles were 5.2 years and 4.2 years, respectively.



#### Note 4 – Credit Facility, Notes Payable and Derivative Instruments

##### Credit Facility

On May 3, 2021, the Company, the Operating Partnership, as borrower, and certain of its subsidiaries (such subsidiaries, the “Subsidiary Guarantors”) entered into an amended and restated \$750 million unsecured syndicated credit facility with JPMorgan Chase Bank, N.A. (“JPMorgan”), as administrative agent (the “Credit Facility”). The Credit Facility consists of a \$350 million term loan component (the “Term Loan”) and a \$400 million revolver component (the “Revolver”). The Credit Facility also includes a \$500 million accordion feature. The Term Loan matures in May 2026 and the Revolver matures in May 2025, with two six-month extension options. Amounts outstanding under the Credit Facility bear interest at a floating rate that is based on LIBOR plus a specified margin based on the Company’s leverage.

The Operating Partnership is subject to a number of financial covenants under the Credit Facility, including, among other things, the following as of the end of each fiscal quarter, (i) a maximum consolidated unsecured leverage ratio of less than 60%, (ii) a maximum consolidated secured leverage ratio of less than 30%, (iii) a maximum consolidated secured recourse leverage ratio of less than 10%, (iv) a minimum fixed charge coverage ratio of 1.50:1.00, (v) a minimum unsecured interest coverage ratio of 1.50:1.00, (vi) a maximum consolidated leverage ratio of less than 60%, and (vii) a minimum net worth of \$345 million plus 75% of all net proceeds raised through equity offerings subsequent to December 31, 2020. As of November 1, 2021, management believed it was in compliance with all of the financial and non-financial covenants contained in the Credit Facility.

The Company has entered into interest rate swaps to hedge its interest rate risk on the Term Loan. For additional information related to the interest rate swaps, see the “Derivative Instruments - Interest Rate Swaps” section herein.

During the nine months ended September 30, 2021, the Company borrowed \$187,700 under the Credit Facility and repaid \$207,200, for a net amount repaid of \$19,500. During the nine months ended September 30, 2020, the Company borrowed \$158,400 under the Credit Facility and repaid \$51,550 for a net amount borrowed of \$106,850. Interest expense incurred on the Credit Facility was \$3,500 and \$11,101 for the three and nine months ended September 30, 2021, respectively, and \$3,743 and \$10,805, for the three and nine months ended September 30, 2020, respectively.

As of September 30, 2021 and December 31, 2020, the Company had the following outstanding borrowings under the Credit Facility:

	September 30, 2021	December 31, 2020
Revolver	\$ 155,700	\$ 175,200
Term Loan	350,000	350,000
Less: Unamortized debt issuance costs	(8,497)	(3,559)
Credit Facility, net	<u>\$ 497,203</u>	<u>\$ 521,641</u>

Costs incurred related to the Credit Facility, net of accumulated amortization, are netted against the Company’s “Credit Facility, net of unamortized debt issuance costs” balance in the accompanying Condensed Consolidated Balance Sheets. The Company paid \$6,177 and \$925 related to amendments and modifications to the Credit Facility as well as fees related to adding properties to the borrowing base during the nine months ended September 30, 2021 and 2020, respectively. The amount paid during the nine months ended September 30, 2021 primarily related to costs incurred in connection with the amendment and restatement of the Credit Facility on May 3, 2021. Amortization expense incurred was \$463 and \$1,239 for the three and nine months ended September 30, 2021, respectively, and \$341 and \$882, for the three and nine months ended September 30, 2020, respectively, and is included in the “Interest Expense” line item in the accompanying Condensed Consolidated Statements of Operations.

##### Reference Rate Reform

On March 5, 2021, the Financial Conduct Authority (“FCA”) announced that USD LIBOR will no longer be published after June 30, 2023. This announcement has several implications, including setting the spread that may be used to automatically convert contracts from LIBOR to the Secured Overnight Financing Rate (“SOFR”). Additionally, banking regulators are encouraging banks to discontinue new LIBOR debt issuances by December 31, 2021.

The Company anticipates that LIBOR will continue to be available at least until June 30, 2023. Any changes adopted by the FCA or other governing bodies in the method used for determining LIBOR may result in a sudden or prolonged increase or decrease in reported LIBOR. If that were to occur, our interest payments could change. In addition, uncertainty about the extent and manner of future changes may result in interest rates and/or payments that are higher or lower than if LIBOR were to remain available in its current form.

The Company has interest rate swaps that are indexed to LIBOR and is monitoring and evaluating the related risks. These risks arise in connection with transitioning contracts to an alternative rate, including any resulting value transfer that may occur, and are likely to vary by contract. The value of loans, securities, or derivative instruments tied to LIBOR, as well as interest rates on our current or future indebtedness, may also be impacted if LIBOR is limited or discontinued. For some instruments the method of transitioning to an alternative reference rate may be challenging, especially if the Company cannot agree with the respective counterparty about how to make the transition.

While the Company expects LIBOR to be available in substantially its current form until at least the end of June 30, 2023, it is possible that LIBOR will become unavailable prior to that point. This could result, for example, if sufficient banks decline to make submissions to the LIBOR administrator. In that case, the risks associated with the transition to an alternative reference rate will be accelerated and magnified.

Alternative rates and other market changes related to the replacement of LIBOR, including the introduction of financial products and changes in market practices, may lead to risk modeling and valuation challenges, such as adjusting interest rate accrual calculations and building a term structure for an alternative rate.

The introduction of an alternative rate also may create additional basis risk and increased volatility as alternative rates are phased in and utilized in parallel with LIBOR.

Adjustments to systems and mathematical models to properly process and account for alternative rates will be required, which may strain the model risk management and information technology functions and result in substantial incremental costs for the Company.

#### Notes Payable, Net of Debt Issuance Costs

The Company's notes payable, net, includes four loans: (1) the Rosedale Loan, (2) the Dumfries Loan, (3) the Cantor Loan, and (4) the West Mifflin Loan, described in detail herein. The following table sets forth the aggregate balances of these loans as of September 30, 2021 and December 31, 2020.

	September 30, 2021	December 31, 2020
Notes payable, gross	\$ 66,349	\$ 66,349
Unamortized debt issuance costs	(644)	(835)
Cumulative principal repayments	(8,308)	(577)
Notes payable, net	<u>\$ 57,397</u>	<u>\$ 64,937</u>

In connection with the aforementioned loans, the Company paid no debt issuance and related costs during the nine months ended September 30, 2021 and \$341 in debt issuance and related costs during the nine months ended September 30, 2020. Amortization expense incurred related to the debt issuance costs was \$62 and \$191 for the three and nine months ended September 30, 2021, respectively, and \$42 and \$110 for the three and nine months ended September 30, 2020, respectively, and is included in the "Interest Expense" line item in the accompanying Condensed Consolidated Statements of Operations.

#### Rosedale Loan

On July 31, 2020, in connection with its acquisition of the Rosedale Facilities, the Company, through certain of its wholly owned subsidiaries, as borrowers, entered into a loan with FVCbank with a principal balance of \$14,800 (the "Rosedale Loan"). The Rosedale Loan has an annual interest rate of 3.85% and matures on July 31, 2025 with principal and interest payable monthly based on a 25-year amortization schedule. The Company, at its option, may prepay the loan, subject to a prepayment fee.

The Company made principal payments of \$270 and \$20 during the nine months ended September 30, 2021 and 2020, respectively. The loan balance as of September 30, 2021 and December 31, 2020 was \$14,421 and \$14,691, respectively. Interest expense incurred on this loan was \$143 and \$425 for the three and nine months ended September 30, 2021, respectively, and \$104 for the three and nine months ended September 30, 2020.

As of September 30, 2021, scheduled principal payments due for each year ended December 31 were as follows:

2021 (three months remaining)	\$	91
2022		376
2023		391
2024		405
2025		13,158
Total	\$	<u>14,421</u>

#### Dumfries Loan

On April 27, 2020, in connection with its acquisition of the Dumfries Facility, the Company, through a wholly-owned subsidiary, assumed a CMBS loan with a principal amount of \$12,074 (the "Dumfries Loan"). The Dumfries Loan has an annual interest rate of 4.68% and matures on June 1, 2024 with principal and interest payable monthly based on a ten-year amortization schedule. The Company, at its option, may prepay the loan, subject to a prepayment premium.

The Company made principal payments of \$204 and \$108 during the nine months ended September 30, 2021 and 2020, respectively. The loan balance as of September 30, 2021 and December 31, 2020 was \$11,695 and \$11,899, respectively. Interest expense incurred on this loan was \$138 and \$413 for the three and nine months ended September 30, 2021, respectively, and \$140 and \$186 for the three and nine months ended September 30, 2020.

As of September 30, 2021, scheduled principal payments due for each year ended December 31 were as follows:

2021 (three months remaining)	\$	71
2022		288
2023		302
2024		11,034
Total	\$	<u>11,695</u>

#### Cantor Loan

On March 31, 2016, through certain of its wholly owned subsidiaries (the "GMR Loan Subsidiaries"), the Company entered into a \$2,097 CMBS loan (the "Cantor Loan"). The Cantor Loan has a maturity date of April 6, 2026 and an annual interest rate of 5.22%. The Cantor Loan required interest-only payments through March 31, 2021 and following that date, requires principal and interest based on a 30-year amortization schedule. Prepayment can only occur within four months prior to the maturity date, subject to earlier defeasance. The Cantor Loan is secured by the assets of the GMR Loan Subsidiaries.

The Company made principal payments of \$172 during the nine months ended September 30, 2021. The loan balance as of September 30, 2021 and December 31, 2020 was \$31,925 and \$32,097. Interest expense incurred on this loan was \$427 and \$1,269 for the three and nine months ended September 30, 2021, respectively, and \$425 and \$1,326 for the three and nine months ended September 30, 2020, respectively.

As of September 30, 2021, scheduled principal payments due for each year ended December 31 were as follows:

2021 (three months remaining)	\$	110
2022		447
2023		471
2024		492
2025		523
Thereafter		29,882
Total	\$	<u>31,925</u>

**West Mifflin Loan**

On September 25, 2015, the Company, through a wholly-owned subsidiary, as borrower, entered into a \$7,378 term loan with Capital One. On September 25, 2020, the Company and Capital One amended the terms of the loan to extend the maturity date to September 25, 2021 and increase the interest rate to 4.25% per annum. The West Mifflin facility serves as collateral for the loan.

The Company made principal payments of \$7,085 and \$105 during the nine months ended September 30, 2021 and 2020, respectively. The loan was paid in full as of September 30, 2021. The loan balance as of December 31, 2020 was \$7,085. Interest expense incurred on this loan was \$97 and \$249 for the three and nine months ended September 30, 2021, respectively, and \$68 and \$203 for the three and nine months ended September 30, 2020, respectively.

**Derivative Instruments - Interest Rate Swaps**

The Company has six interest rate swaps with a total notional amount of \$350 million that are used to manage its interest rate risk and fix the LIBOR component on the Term Loan. An aggregate of \$ 150 million of the swaps mature in August 2023 and the remaining \$200 million mature in August 2024. In addition, the Company has five forward starting interest rate swaps that will be effective on the maturity dates of the existing interest rate swaps. The forward starting swaps each have a maturity date of April 2026 and will fix the LIBOR component on the Term Loan through its maturity. Currently, the interest rate swaps fix the LIBOR component of the Term Loan at a rate of 1.91% through August 2023. Subsequently, from August 2023 to August 2024 the LIBOR component of the Term Loan rate will be fixed at 1.61%. Finally, from August 2024 to April 2026 the LIBOR component of the Term Loan rate will be fixed at 1.45%.

The Company records the swaps either as an asset or a liability measured at its fair value at each reporting period. When hedge accounting is applied, the change in the fair value of derivatives designated and that qualify as cash flow hedges is (i) recorded in accumulated other comprehensive loss in the equity section of the Company's Condensed Consolidated Balance Sheets and (ii) subsequently reclassified into earnings as interest expense for the period that the hedged forecasted transactions affect earnings. If specific hedge accounting criteria are not met, changes in the Company's derivative instruments' fair value are recognized currently as an adjustment to net income.

The Company's interest rate swaps are not traded on an exchange. The Company's interest rate swaps are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis based on the expected size of future cash flows on a discounted basis and incorporating a measure of non-performance risk. The fair values are based on Level 2 inputs within the framework of ASC Topic 820, "Fair Value Measurement." The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivative instruments.

The fair value of the Company's interest rate swaps was a net liability of \$1,851 and \$18,086 as of September 30, 2021 and December 31, 2020, respectively. The gross balances are included in the "Derivative Asset" and "Derivative Liability" line items on the Company's Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020, respectively.

The table below details the components of the amounts presented on the accompanying Condensed Consolidated Statements of Comprehensive Income (Loss) recognized on the Company's interest rate swaps designated as cash flow hedges for the three and nine months ended September 30, 2021 and 2020:

	<b>Three Months Ended</b>		<b>Nine Months Ended September 30,</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2021</b>	<b>2020</b>	<b>2021</b>	<b>2020</b>
Amount of (gain) loss recognized in other comprehensive income (loss)	\$ (227)	\$ (451)	\$ (1,523)	\$ 16,313
Amount of loss reclassified from accumulated other comprehensive loss into interest expense	(1,611)	(1,552)	(4,750)	(3,336)
<b>Total change in accumulated other comprehensive loss</b>	<b>\$ (1,838)</b>	<b>\$ (2,003)</b>	<b>\$ (6,273)</b>	<b>\$ 12,977</b>

During the next twelve months, the Company estimates that an additional \$6,224 will be reclassified as an increase to interest expense. Additionally, during the three and nine months ended September 30, 2021, the Company recorded total interest expense in its Condensed Consolidated Statements of Operations of \$4,830 and \$14,887, respectively.

#### Weighted-Average Interest Rate and Term

The weighted average interest rate and term of the Company's debt was 2.91% and 4.53 years at September 30, 2021, compared to 3.17% and 2.79 years as of December 31, 2020.

#### Note 5 – Equity

##### Preferred Stock

The Company's charter authorizes the issuance of 10,000 shares of preferred stock, par value \$0.001 per share. As of September 30, 2021 and December 31, 2020, there were 3,105 shares of Series A Cumulative Redeemable Preferred Stock ("Series A Preferred Stock"), issued and outstanding. The Series A Preferred Stock has a liquidation preference of \$25 per share.

Preferred stock dividend activity for the nine months ended September 30, 2021 is summarized in the following table:

<u>Date Announced</u>	<u>Record Date</u>	<u>Applicable Quarter</u>	<u>Payment Date</u>	<u>Quarterly Dividend</u>	<u>Dividends per Share</u>
December 16, 2020	January 15, 2021	Q4 2020	February 1, 2021	\$ 1,455	\$ 0.46875
March 3, 2021	April 15, 2021	Q1 2021	April 30, 2021	\$ 1,455	\$ 0.46875
June 10, 2021	July 15, 2021	Q2 2021	August 2, 2021	\$ 1,455	\$ 0.46875
September 10, 2021	October 15, 2021	Q3 2021	November 1, 2021	\$ 1,455 <sup>(1)</sup>	\$ 0.46875

<sup>(1)</sup> Two months of this amount, equal to \$970, was accrued at September 30, 2021.

The holders of the Series A Preferred Stock are entitled to receive dividend payments only when, as and if declared by the Company's board of directors (the "Board") (or a duly authorized committee of the Board). Dividends will accrue or be payable in cash from the original issue date, on a cumulative basis, quarterly in arrears on each dividend payment date at a fixed rate per annum equal to 7.50% of the liquidation preference of \$25.00 per share (equivalent to \$1.875 per share on an annual basis). Dividends on the Series A Preferred Stock will be cumulative and will accrue whether or not (i) funds are legally available for the payment of those dividends, (ii) the Company has earnings or (iii) those dividends are declared by the Board. The quarterly dividend payment dates on the Series A Preferred Stock are January 31, April 30, July 31 and October 31 of each year. During each of the nine-month periods ended September 30, 2021 and 2020, the Company paid preferred dividends of \$4,366.

##### Common Stock

The Company has 500,000 authorized shares of common stock, \$0.001 par value. As of September 30, 2021 and December 31, 2020, there were 64,208 and 49,461 outstanding shares of common stock, respectively.

Common stock dividend activity for the nine months ended September 30, 2021 is summarized in the following table:

<u>Date Announced</u>	<u>Record Date</u>	<u>Applicable Quarter</u>	<u>Payment Date</u>	<u>Dividend Amount<sup>(1)</sup></u>	<u>Dividends per Share</u>
December 16, 2020	December 28, 2020	Q4 2020	January 11, 2021	\$ 10,573	\$ 0.20
March 3, 2021	March 24, 2021	Q1 2021	April 8, 2021	\$ 13,260	\$ 0.205
June 10, 2021	June 24, 2021	Q2 2021	July 8, 2021	\$ 13,964	\$ 0.205
September 10, 2021	September 24, 2021	Q3 2021	October 8, 2021	\$ 13,961	\$ 0.205

<sup>(1)</sup> Includes distributions on outstanding LTIP Units and OP Units.

During the nine months ended September 30, 2021 and 2020, the Company paid total dividends on its common stock, LTIP Units and OP Units in the aggregate amount of \$38,539 and \$29,588, respectively.

As of September 30, 2021 and December 31, 2020, the Company had accrued dividend balances of \$377 and \$927 for dividends payable on the aggregate annual and long-term LTIP Units that are subject to retroactive receipt of dividends on the amount of LTIP Units ultimately earned. During the nine months ended September 30, 2021, \$192 of dividends were accrued and \$742 of dividends were paid related to these units. During the nine months ended September 30, 2020, \$512 of dividends were accrued and \$576 of dividends were paid related to these units.

The amount of the dividends paid to the Company's stockholders is determined by the Board and is dependent on a number of factors, including funds available for payment of dividends, the Company's financial condition and capital expenditure requirements except that, in accordance with the Company's organizational documents and Maryland law, the Company may not make dividend distributions that would: (i) cause it to be unable to pay its debts as they become due in the usual course of business; (ii) cause its total assets to be less than the sum of its total liabilities plus senior liquidation preferences; or (iii) jeopardize its ability to maintain its qualification as a REIT.

#### Capital Raising Activity

On March 18, 2021, the Company closed an underwritten public offering of its common stock, including the related option to purchase additional shares granted to the underwriters. These transactions resulted in the issuance of 8,625 shares of the Company's common stock at a public offering price of \$13.30 per share, resulting in net proceeds to the Company of \$109,550.

In August 2020, the Company and the Operating Partnership entered into a Sales Agreement with certain sales agents, pursuant to which the Company may offer and sell, from time to time, up to \$150 million of its common stock (the "2020 ATM Program"). During the nine months ended September 30, 2021, the Company generated net proceeds of \$85,300 through equity issuances of 6,061 shares of the Company's common stock at an average offering price of \$14.29 per share through the 2020 ATM Program. As of November 1, 2021, the Company had \$23 million remaining under the 2020 ATM Program.

#### **OP Units**

During the nine months ended September 30, 2021, three OP Unit holders redeemed an aggregate of 62 OP Units for shares of the Company's common stock with an aggregate redemption value of \$919. During the year ended December 31, 2020, four OP Unit holders redeemed an aggregate of 1,379 OP Units for shares of the Company's common stock with an aggregate redemption value of \$7,882.

As of September 30, 2021 and December 31, 2020, there were 1,702 and 1,764 OP Units issued and outstanding, respectively, with an aggregate value of \$9,080 and \$9,999, respectively. The OP Unit value at issuance and redemption is based on the Company's closing share price on the date of the respective transaction and is included as a component of noncontrolling interest equity in the Company's Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020. The Company has sufficient shares of common stock authorized pursuant to its charter to cover the redemption of outstanding OP Units.

#### **Note 6 – Related Party Transactions**

##### **Management Agreement**

On July 9, 2020, the Company completed the management internalization transaction. Prior to the completion of this transaction, the Company was subject to a management agreement dated July 1, 2016, by and between the Company and its former advisor.

##### **Management Fees and Accrued Management Fees**

As a result of the completion of the management internalization transaction, for the three months ended September 30, 2020, no management fees were incurred and expensed by the Company. For the nine months ended September 30, 2020, prior to the completion of the management internalization transaction, management fees of \$4,024 were incurred and expensed by the Company. No incentive management fee was incurred by the Company during the three and nine months ended September 30, 2020.

**Related Party Balances**

The due from related parties balance as of September 30, 2021 and December 31, 2020 was \$275 and \$103, respectively. These balances primarily consist of taxes paid on behalf of LTIP Unit and OP Unit holders that are reimbursable to the Company. The Company had no amounts due to related parties as of September 30, 2021 and December 31, 2020.

**Pro Forma Financial Information**

On July 9, 2020, the Company acquired all of the outstanding shares of capital stock of the parent company of its former advisor. The accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2021 include the operations of the business acquired for the full nine-month period. The table below presents the unaudited revenue and net income attributable to common stockholders on a pro forma basis for the nine months ended September 30, 2020, as if the transaction occurred on January 1, 2020. The pro forma results are not necessarily indicative of the results that would have occurred if the business combination had occurred on the first day of the period presented, nor does the pro forma information purport to represent the results of operations for future periods.

	<b>Nine Months Ended September 30, 2020</b>	
	(unaudited, in thousands)	
Pro forma total revenue	\$	68,801
Pro forma net income attributable to common stockholders	\$	4,469

**Note 7 – Stock-Based Compensation****2016 Equity Incentive Plan**

The 2016 Equity Incentive Plan, as amended (the “Plan”), is intended to assist the Company and its affiliates in recruiting and retaining employees of the Company, members of the Board, executive officers of the Company, and individuals who provide services to the Company and its affiliates.

The Plan is intended to permit the grant of both qualifying and non-qualified options and the grant of stock appreciation rights, restricted stock, unrestricted stock, awards of restricted stock units, performance awards and other equity-based awards (including LTIP Units). On May 26, 2021, the Company’s stockholders approved an amendment to the Plan to increase the number of authorized shares available for issuance under the Plan by 1,500 shares. Based on the grants outstanding as of September 30, 2021, there were 1,469 shares of common stock that remain available to be granted under the Plan. Units subject to awards under the Plan that are forfeited, cancelled, lapsed, settled in cash or otherwise expired (excluding shares withheld to satisfy exercise prices or tax withholding obligations) are available for grant.

**Time-Based Grants**

During the nine months ended September 30, 2021, pursuant to the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), the Board approved the following LTIP Unit activity:

<b>Date</b>	<b>Description</b>	<b>Number of Units Issued</b>	<b>Vesting Dates</b>
March 2, 2021	Final awards under the 2018 Long-Term Incentive Plan	220	50% on March 2, 2021; and 50% on March 2, 2022
March 2, 2021	Final awards under the 2020 Annual Incentive Plan	267	50% on March 2, 2021; and 50% on March 2, 2022
March 2, 2021	Time-based awards under the 2021 Long-Term Incentive Plan	56	100% on March 2, 2024
May 26, 2021	Annual awards to independent directors	25	100% on May 26, 2022

During the nine months ended September 30, 2021, there were 17 time-based LTIP Units forfeited. A detail of the Company's outstanding time-based LTIP Units as of September 30, 2021 is as follows:

Vested units	1,452
Unvested units	738
LTIP Units outstanding as of September 30, 2021	<u>2,190</u>

#### Performance Based Awards

The Board has approved annual performance-based LTIP awards ("Annual Awards") and long-term performance-based LTIP awards ("Long-Term Awards") to the executive officers and other employees of the Company. As described below, the Annual Awards have one-year performance periods and the Long-Term Awards have three-year performance periods. In addition to meeting specified performance metrics, vesting in both the Annual Awards and the Long-Term Awards is subject to service requirements.

During the nine months ended September 30, 2021 there were eight performance-based LTIP awards forfeited. A detail of the Company's Long-Term Awards under the 2019 and 2020 programs, and the Annual Awards and Long-Term Awards under the 2021 program as of September 30, 2021 is as follows:

2019 Long-Term Awards	82
2020 Long-Term Awards	68
2021 Annual Awards <sup>(1)</sup>	88
2021 Long-Term Awards <sup>(2)</sup>	74
Total target performance awards as of September 30, 2021	<u>312</u>

- (1) Approved by the Board on March 2, 2021. The number of target LTIP Units was based on the average closing price of the Company's common stock reported on the New York Stock Exchange ("NYSE") over the 15 trading days preceding the grant date.
- (2) Approved by the Board on March 2, 2021. The number of target LTIP Units was based on the fair value of the Long-Term Awards as determined by an independent valuation consultant.

*Annual Awards.* The Annual Awards are subject to the terms and conditions of LTIP Annual Award Agreements ("LTIP Annual Award Agreements") between the Company and each grantee.

The Compensation Committee and Board established performance goals for the year ending December 31, 2021, as set forth in the 2021 LTIP Annual Award Agreements (the "Performance Goals") that will be used to determine the number of LTIP Units earned by each grantee. As of September 30, 2021, management estimated that the Performance Goals would be met at a 105% level and, accordingly, estimated that 105% of the 2021 target Annual Awards were expected to be earned at the end of the performance period, and accordingly, cumulative stock-based compensation expense during the three and nine months ended September 30, 2021 reflects management's estimate that 105% of these awards will be earned. As soon as reasonably practicable following the first anniversary of the Annual Awards grant date, the Compensation Committee and Board will determine the extent to which the Company has achieved each of the Performance Goals (expressed as a percentage) and, based on such determination, will calculate the number of LTIP Units that each grantee is entitled to receive. Each grantee may earn up to 150% of the number of his/her target LTIP Units. Any 2021 Annual Award LTIP Units that are not earned will be forfeited and cancelled.

*Vesting.* LTIP Units that are earned as of the end of the applicable performance period will be subject to vesting, subject to continued employment through each vesting date, in two installments as follows: 50% of the earned LTIP Units will become vested on the date in 2022 that the Board approves the number of LTIP Units to be awarded pursuant to the performance components set forth in the 2021 LTIP Annual Award Agreements and 50% of the earned LTIP Units become vested on the one year anniversary of the initial vesting date. Vesting may be accelerated under certain circumstances such as a "change-in-control" transaction or a "qualified termination" event.

*Distributions.* Distributions equal to the dividends declared and paid by the Company will accrue during the applicable performance period on the maximum number of LTIP Units that the grantee could earn and will be paid with respect to all of the earned LTIP Units at the conclusion of the applicable performance period, in cash or by the issuance of additional LTIP Units at the discretion of the Compensation Committee.



*Long-Term Awards.* The Long-Term Awards are subject to the terms and conditions of their related LTIP Long-Term Award Agreements (collectively the “LTIP Long-Term Award Agreements”) between the Company and each grantee. The number of LTIP Units that each grantee earns under the LTIP Long-Term Award Agreements will be determined following the conclusion of a three-year performance period based on the Company’s total stockholder return (“TSR”), which is determined based on a combination of appreciation in stock price and dividends paid during the performance period. Each grantee may earn up to 200% of the number of target LTIP Units covered by the grantee’s Long-Term Award. Any target LTIP Units that are not earned will be forfeited and cancelled. The number of LTIP Units earned under the Long-Term Awards will be determined as soon as reasonably practicable following the end of the applicable three-year performance period based on the Company’s TSR on an absolute basis (as to 75% of the Long-Term Award) and relative to the companies that comprised the former SNL Healthcare REIT Index (the “Index”) (as to 25% of the Long-Term Award).

*Vesting.* LTIP Units that are earned as of the end of the applicable three-year performance period will be subject to forfeiture restrictions that will lapse (“vesting”), subject to continued employment through each vesting date as follows; 50% of the earned LTIP Units will vest upon the third anniversary of the respective grant dates and the remaining 50% will vest on the fourth anniversary of the respective grant dates. Vesting may be accelerated under certain circumstances such as a “change-in-control” transaction or a “qualified termination” event.

*Distributions.* Pursuant to the LTIP Long-Term Award Agreements, distributions equal to the dividends declared and paid by the Company will accrue during the applicable performance period on the maximum number of LTIP Units that the grantee could earn and will be paid with respect to all of the earned LTIP Units at the conclusion of the applicable performance period, in cash or by the issuance of additional LTIP Units at the discretion of the Compensation Committee.

### Stock-Based Compensation Expense

The Company’s prospective compensation expense for all unvested LTIP Units, Annual Awards, and Long-Term Awards is recognized using the adoption date fair value of the awards, with no remeasurement required. Compensation expense for future LTIP Unit grants, Annual Awards, and Long-Term Awards is based on the grant date fair value of the units/awards, with no subsequent remeasurement required.

As the Long-Term Awards involve market-based performance conditions, the Company utilizes a Monte Carlo simulation to provide a grant date fair value for expense recognition. The Monte Carlo simulation is a generally accepted statistical technique used, in this instance, to simulate a range of possible future stock prices for the Company and the members of the Index over the Performance Periods. The purpose of this modeling is to use a probabilistic approach for estimating the fair value of the performance share award.

The assumptions used in the Monte Carlo simulation include beginning average stock price, valuation date stock price, expected volatilities, correlation coefficients, risk-free rate of interest, and expected dividend yield. The beginning average stock price is the beginning average stock price for the Company and each member of the Index for the five trading days leading up to the grant date of the Long-Term Award. The valuation date stock price is the closing stock price of the Company and each of the peer companies in the Index on the grant dates of the Long-Term Awards. The expected volatilities are modeled using the historical volatilities for the Company and the members of the Index. The correlation coefficients are calculated using the same data as the historical volatilities. The risk-free rate of interest is taken from the U.S. Treasury website and relates to the expected life of the remaining performance period on valuation or revaluation. Lastly, the dividend yield assumption is 0.0%, which is mathematically equivalent to reinvesting dividends in the issuing entity, which is part of the Company’s award agreement assumptions.

Below are details regarding certain of the assumptions for the Long-Term Awards using Monte Carlo simulations:

	<u>2021 Long-Term Awards</u>	<u>2020 Long-Term Awards</u>	<u>2019 Long-Term Awards</u>
Fair value	\$ 14.86	\$ 13.47	\$ 10.07
Target awards	76	70	82
Volatility	42.37 %	28.75 %	31.7 %
Risk-free rate	0.26 %	0.72 %	2.5 %
Dividend assumption	reinvested	reinvested	reinvested
Expected term in years	3	3	3

The Company incurred stock compensation expense of \$1,241 and \$4,568 for the three and nine months ended September 30, 2021, respectively, and \$1,572 and \$3,391, for the three and nine months ended September 30, 2020, respectively, related to the grants awarded under the Plan. Compensation expense is included within “General and Administrative” expense in the Company’s Condensed Consolidated Statements of Operations.

As of September 30, 2021, total unamortized compensation expense related to these awards of approximately \$0.1 million is expected to be recognized over a weighted average remaining period of 1.8 years.

#### **Note 8 – Leases**

The Company operates as both a lessor and a lessee. As a lessor, the Company is required under ASC Topic 842 to account for leases using an approach that is substantially similar to ASC Topic 840’s guidance for operating leases and other leases such as sales-type leases and direct financing leases. In addition, ASC Topic 842 requires lessors to capitalize and amortize only incremental direct leasing costs. As a lessee, the Company is required under the new standard to apply a dual approach, classifying leases, such as ground leases, as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. ASC Topic 842 also requires lessees to record a right of use asset and a lease liability for all leases with an initial term of greater than a year regardless of their classification. The Company has also elected the practical expedient not to recognize right of use assets and lease liabilities for leases with a term of a year or less.

#### **Information as Lessor Under ASC Topic 842**

To generate positive cash flow, as a lessor, the Company leases its facilities to tenants in exchange for fixed monthly payments that cover rent, property taxes, insurance and certain cost recoveries, primarily common area maintenance (“CAM”). The Company’s leases were determined to be operating leases and have a portfolio-average-lease-years remaining of approximately 10 years. Payments from the Company’s tenants for CAM are considered nonlease components that are separated from lease components and are generally accounted for in accordance with the revenue recognition standard. However, the Company qualified for and elected the practical expedient related to combining the components because the lease component is classified as an operating lease and the timing and pattern of transfer of CAM income, which is not the predominant component, is the same as the lease component, for all asset classes. As such, consideration for CAM is accounted for as part of the overall consideration in the lease. Payments from customers for property taxes and insurance are considered non-components of the lease and therefore no consideration is allocated to them because they do not transfer a good or service to the customer. Fixed contractual payments from the Company’s leases are recognized on a straight-line basis over the terms of the respective leases. This means that, with respect to a particular lease, actual amounts billed in accordance with the lease during any given period may be higher or lower than the amount of rental revenue recognized for the period. Straight-line rental revenue is commenced when the tenant assumes control of the leased premises. Accrued straight-line rents receivable represents the amount by which straight-line rental revenue exceeds rents currently billed in accordance with lease agreements.

Some of the Company’s leases are subject to annual changes in the Consumer Price Index (“CPI”). Although increases in CPI are not estimated as part of the Company’s measurement of straight-line rental revenue, for leases with base rent increases based on CPI, the amount of rent revenue recognized is adjusted in the period the changes in CPI are measured and effective. Additionally, some of the Company’s leases have extension options.

Initial direct costs, primarily commissions, related to the leasing of our facilities are capitalized when material as incurred. Capitalized leasing costs are amortized on a straight-line basis over the remaining useful life of the respective leases. All other costs to negotiate or arrange a lease are expensed as incurred.

Lease-related receivables, which include accounts receivable and accrued straight-line rents receivable, are reduced for credit losses, if applicable. The Company regularly evaluates the collectability of its lease-related receivables. The Company’s evaluation of collectability primarily consists of reviewing past due account balances and considering such factors as the credit quality of our tenant, historical trends of the tenant and changes in tenant payment terms. If the Company’s assumptions regarding the collectability of lease-related receivables prove incorrect, the Company could experience credit losses in excess of what was recognized in rental and other revenues.

The Company recognized \$29,967 and \$85,492 of rental revenue related to operating lease payments for the three and nine months ended September 30, 2021, respectively, and \$25,055 and \$68,623 of rental revenue related to operating lease payments for the

three and nine months ended September 30, 2020, respectively. Of these amounts, \$1,822 and \$4,730 relate to variable rental revenue for the three and nine months ended September 30, 2021, respectively, and \$1,136 and \$3,739 relate to variable rental revenue for the three and nine months ended September 30, 2020, respectively.

The aggregate annual cash to be received by the Company on the noncancelable operating leases related to its portfolio as of September 30, 2021 is as follows for the subsequent years ended December 31:

2021 (three months remaining)	\$	25,919
2022		103,360
2023		100,638
2024		92,387
2025		79,490
Thereafter		414,112
Total	\$	<u>815,906</u>

#### Information as Lessee Under ASC Topic 842

The Company has seven buildings located on land that is subject to operating ground leases with a weighted average remaining term of approximately 40 years. Rental payments on these leases are adjusted periodically based on either the CPI or on a pre-determined schedule. The monthly payments on a pre-determined schedule are recognized on a straight-line basis over the terms of the respective leases. Changes in the CPI are not estimated as part of our measurement of straight-line rental expense. The Company used a weighted average discount rate of approximately 7.5%, which was derived, using a portfolio approach, from our assessment of the credit quality of the Company and adjusted to reflect secured borrowing, estimated yield curves and long-term spread adjustments over appropriate tenors. Some of the Company's ground leases contain extension options and, where we determined it was reasonably certain that an extension would occur, they were included in our calculation of the right of use asset and liability. The Company recognized approximately \$35 and \$111 of ground lease expense during the three and nine months ended September 30, 2021, respectively, of which \$26 and \$88 was paid in cash. The Company recognized approximately \$41 and \$122 of ground lease expense during the three and nine months ended September 30, 2020, respectively, of which \$26 and \$64 was paid in cash.

The following table sets forth the undiscounted cash flows of our scheduled obligations for future lease payments on operating ground leases at September 30, 2021, and a reconciliation of those cash flows to the operating lease liability at September 30, 2021:

2021 (three months remaining)	\$	105
2022		442
2023		206
2024		162
2025		163
Thereafter		6,207
Total		<u>7,285</u>
Discount		(4,001)
Lease liability	\$	<u>3,284</u>

#### Tenant Concentration

During the nine months ended September 30, 2021, the Company's rental revenues were derived from 177 tenants leasing 102 facilities. During this period there were no tenants with rental revenue that exceeded 10% of the Company's rental revenue.

#### Note 9 – Commitments and Contingencies

##### Litigation

The Company is not presently subject to any material litigation nor, to its knowledge, is any material litigation threatened against the Company, which if determined unfavorably to the Company, would have a material adverse effect on the Company's financial position, results of operations, or cash flows.

**Environmental Matters**

The Company follows a policy of monitoring its properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at its properties, the Company is not currently aware of any environmental liability with respect to its properties that would have a material effect on its financial position, results of operations, or cash flows. Additionally, the Company is not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability that management believes would require additional disclosure or the recording of a loss contingency.

**Note 10 – Subsequent Events**

**Completed Disposition of a Property**

On October 13, 2021, the Company sold a medical office building located in Prescott, Arizona receiving gross proceeds of \$5.5 million, resulting in a gain of approximately \$1.1 million. The Company acquired the facility in February 2017.

**Property Under Contract for Sale**

On October 5, 2021, the Company entered into an agreement to sell a medical office building located in Belpre, Ohio for gross proceeds of approximately \$44.6 million. The property had a net book value of approximately \$29.7 million as of September 30, 2021. The transaction is expected to be completed no earlier than March 2022. The buyer is currently in the due diligence period and the transaction is subject to various closing contingencies. Accordingly, the transaction may not close on a timely basis or the buyer may terminate the purchase agreement and not close the transaction. The Company acquired the facility as part of a portfolio of four medical office buildings in April 2018.

## Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

*The following discussion should be read in conjunction with our financial statements, including the notes to those financial statements, included elsewhere in this Quarterly Report on Form 10-Q (this “Report”). Some of the comments we make in this section are forward-looking statements within the meaning of the federal securities laws. For a complete discussion of forward-looking statements, see the section below entitled “Special Note Regarding Forward-Looking Statements.” Certain risk factors may cause actual results, performance or achievements to differ materially from those expressed or implied by the following discussion. For a discussion of such risk factors, see Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2020, that was filed with the U.S. Securities and Exchange Commission (the “SEC” or the “Commission”) on March 8, 2021 and Item 1A. Risk Factors of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, that was filed with the SEC on May 7, 2021. Unless otherwise indicated, all dollar and share amounts in the following discussion are presented in thousands.*

### Special Note Regarding Forward-Looking Statements

This Report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In particular, statements pertaining to our trends, liquidity, capital resources, and the healthcare industry and the healthcare real estate markets and opportunity, among others, contain forward-looking statements. You can identify forward-looking statements by the use of forward-looking terminology including, but not limited to, “believes,” “expects,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “estimates” or “anticipates” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans or intentions.

Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

- the effects of the ongoing novel coronavirus (“COVID-19”) pandemic, which are highly uncertain, cannot be predicted and will depend upon future developments, including the severity of COVID-19, the duration of the outbreak and potential resurgences (including any related variants of the COVID-19 virus such as the Delta variant, or others), the duration of existing or new social distancing and shelter-in-place orders, further mitigation strategies taken by applicable government authorities, the availability and distribution of vaccines, vaccination rates, adequate testing and treatments and the prevalence of widespread immunity to COVID-19;
- defaults on or non-renewal of leases by tenants;
- our ability to collect rents;
- our ability to satisfy the covenants in our existing and any future debt agreements;
- decreased rental rates or increased vacancy rates, including expected rent levels on acquired properties;
- difficulties in identifying healthcare facilities to acquire and completing such acquisitions;
- adverse economic or real estate conditions or developments, either nationally or in the markets in which our facilities are located;
- our failure to generate sufficient cash flows to service our outstanding obligations;
- fluctuations in interest rates and increased operating costs;
- our failure to effectively hedge our interest rate risk;
- our ability to satisfy our short and long-term liquidity requirements;
- our ability to deploy the debt and equity capital we raise;
- our ability to raise additional equity and debt capital on terms that are attractive or at all;
- our ability to make distributions on shares of our common and preferred stock;
- expectations regarding the timing and/or completion of any acquisition;
- expectations regarding the timing and/or completion of dispositions, and the expected use of proceeds therefrom;
- general volatility of the market price of our common and preferred stock;
- changes in our business or our investment or financing strategy;
- our dependence upon key personnel whose continued service is not guaranteed;

- our ability to identify, hire and retain highly qualified personnel in the future;
- the degree and nature of our competition;
- changes in healthcare laws, governmental regulations, tax rates and similar matters;
- changes in current healthcare and healthcare real estate trends;
- changes in expected trends in Medicare, Medicaid and commercial insurance reimbursement trends;
- competition for investment opportunities;
- our failure to successfully integrate acquired healthcare facilities;
- our expected tenant improvement expenditures;
- changes in accounting policies generally accepted in the United States of America (“GAAP”);
- lack of or insufficient amounts of insurance;
- other factors affecting the real estate industry generally;
- changes in the tax treatment of our distributions;
- our failure to qualify and maintain our qualification as a real estate investment trust (“REIT”) for U.S. federal income tax purposes;
- our ability to qualify for the safe harbors from the “100% Prohibited Transactions Tax” under the REIT rules with respect to our property dispositions; and
- limitations imposed on our business and our ability to satisfy complex rules relating to REIT qualification for U.S. federal income tax purposes.

See Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020, that was filed with the SEC on March 8, 2021 and Item 1A. Risk Factors of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, that was filed with the SEC on May 7, 2021, for further discussion of these and other risks, as well as the risks, uncertainties and other factors discussed in this Report and identified in other documents we may file with the SEC from time to time. You should carefully consider these risks before making any investment decisions in our company. New risks and uncertainties may also emerge from time to time that could materially and adversely affect us. While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes after the date of this Report, except as required by applicable law. You should not place undue reliance on any forward-looking statements that are based on information currently available to us or the third parties making the forward-looking statements.

## Overview

Global Medical REIT Inc. (the “Company,” “us,” “we,” or “our”) is a Maryland corporation engaged primarily in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to strong healthcare systems and physician groups with leading market share.

We elected to be taxed as a REIT for U.S. federal income tax purposes commencing with our taxable year ended December 31, 2016. We conduct our business through an umbrella partnership real estate investment trust, or UPREIT, structure in which our properties are owned by wholly owned subsidiaries of our operating partnership, Global Medical REIT L.P. (the “Operating Partnership”). Our wholly owned subsidiary, Global Medical REIT GP LLC, is the sole general partner of our Operating Partnership and, as of September 30, 2021, we owned 94.28% of the outstanding equity interests in our Operating Partnership.

## Our Business Objectives and Investment Strategy

Our principal business objective is to provide attractive, risk-adjusted returns to our stockholders through a combination of (i) reliable dividends and (ii) long-term capital appreciation. Our primary strategies to achieve our business objective are to:

- construct a portfolio of healthcare facilities that are primarily located in secondary markets and suburbs of primary markets and are situated to take advantage of the aging of the U.S. population and the decentralization of the healthcare delivery system;
- lease our properties to healthcare tenants with profitable practices that are utilized by an aging population and are highly dependent on their purpose-built real estate to deliver core medical procedures, such as cardiovascular treatment, rehabilitation, eye surgery, gastroenterology, oncology treatment and orthopedics;

- set aside a portion of our property portfolio for opportunistic acquisitions, including (i) certain acute-care hospitals and long-term acute care facilities (LTACs), that we believe provide premium, risk-adjusted returns, (ii) health system corporate office and administrative buildings, which we believe will help us develop relationships with larger health systems and (iii) behavioral and mental health facilities that are operated by national or regional operators and are located in markets that demonstrate a need for such services; and
- lease our facilities under triple-net leases with contractual annual rent escalations.

### **Corporate Sustainability and Social Responsibility**

Our business values integrate environmental sustainability, social responsibility and strong governance practices throughout our organization.

We continue to improve and expand our efforts in the corporate sustainability arena through tenant outreach and data collection to benchmark our portfolio's energy consumption and efficiency. On July 1, 2021, we submitted our second GRESB assessment, and we are working with third-party experts to support our energy monitoring efforts. We have also begun to explore potential projects with solar energy providers and on-property electric vehicle charging solutions.

Our commitment to employee engagement remains a high-priority, as we continue to make accommodations for health, safety, and work-life balance. With this commitment in mind, and in response to the Company's growth, we have modestly grown our team during 2021.

During the first quarter of 2021, our employee ESG working group engaged Georgetown University's Steers Center for Global Real Estate to help us identify social responsibility initiatives. Their recommendation led to a pilot project that provides transportation to healthcare facilities for those in need. We are working with a ride-share provider and national charitable organization to implement the project in the greater Phoenix, Arizona metro area.

Our Board of Directors (the "Board") continues to lead our social and governance efforts. With its diverse composition, our Board is a strong example of inclusive leadership. In 2021, the Board continued to improve our corporate governance structure by adopting an anti-hedging and anti-pledging policy and executive equity ownership guidelines. The Board has also formed an ESG working group and has worked with management to identify an environmental, social, governance and resilience framework that can guide our ESG work going forward.

### **Climate Change**

We take climate change and the risks associated with climate change seriously. We are committed to aligning our investment strategy with science and have begun to monitor our portfolio for climate risk factors. We will use this information to evaluate our insurance needs and risk management approach. In addition, the energy consumption data that we are collecting will be used to assess facilities' carbon emission levels. Capturing and tracking this information will help inform future mitigation and remediation efforts where possible. To that end we are exploring ways to mitigate climate risk, should it be present, in our acquisition strategy, as well as ways to contribute to the reduction of climate impact through proactive asset management that looks for ways to incorporate renewable energy resources and energy utilization reduction. We stand with our communities, tenants, and stockholders in supporting meaningful solutions that address this global challenge and contribute to the sustainability of our business objectives.

### **Impact of COVID-19 and Business Outlook**

Although COVID-19 vaccines are generally widely available in the United States, the rate of vaccination has slowed, the COVID-19 pandemic has not ended and its effects on the U.S. economy will have lasting effects. New and potentially more virulent variants of COVID-19 have been identified, such as the Delta variant, a rapidly spreading strain, that has led to a recent rise in hospitalization and infection rates. Therefore, the risk of further resurgence and possible reimposition of restrictions remains.

Although the COVID-19 pandemic has not had a material effect on our business, a resurgence of COVID-19, including its variants (such as the Delta variant), that affects our tenants' ability to pay rent to us, our lenders' ability to lend to us, or our ability to raise equity capital could have a material adverse effect on us.

## Executive Summary

The following table summarizes the material changes in our business and operations during the periods presented. The three and nine months ended September 30, 2020 included a one-time charge related to the portion of consideration paid for the management internalization transaction that was attributed to the settlement of a preexisting contractual relationship of \$12.1 million, as well as related expenses incurred associated with the transaction.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2020	2021	2020
	(in thousands, except per share and unit amounts)			
Rental revenue	\$ 29,967	\$ 25,055	\$ 85,492	\$ 68,623
Depreciation and amortization expense	\$ 11,942	\$ 9,517	\$ 34,222	\$ 26,215
Interest expense	\$ 4,830	\$ 4,864	\$ 14,887	\$ 13,616
General and administrative expense	\$ 3,852	\$ 4,027	\$ 12,519	\$ 7,509
Management internalization expense	\$ —	\$ 12,580	\$ —	\$ 14,005
Net income (loss) attributable to common stockholders per share	\$ 0.06	\$ (0.22)	\$ 0.13	\$ (0.19)
FFO per share and unit <sup>(1)</sup>	\$ 0.23	\$ (0.03)	\$ 0.67	\$ 0.34
AFFO per share and unit <sup>(1)</sup>	\$ 0.24	\$ 0.23	\$ 0.71	\$ 0.65
Dividends per share of common stock	\$ 0.205	\$ 0.20	\$ 0.615	\$ 0.60
Weighted average common stock outstanding	64,204	46,908	59,398	45,503
Weighted average OP Units outstanding	1,707	1,958	1,741	2,250
Weighted average LTIP Units outstanding	2,198	1,367	2,040	1,143
Total weighted average shares and units outstanding	68,109	50,233	63,179	48,896

(1) See “—Non-GAAP Financial Measures,” for a description of our non-GAAP financial measures and a reconciliation of our non-GAAP financial measures.

	As of	
	September 30, 2021	December 31, 2020
	(dollars in thousands)	
Investment in real estate, gross	\$ 1,311,509	\$ 1,142,905
Total debt, net	\$ 554,600	\$ 586,578
Weighted average interest rate	2.91 %	3.17 %
Total equity (including noncontrolling interest)	\$ 630,225	\$ 457,760
Net leasable square feet	4,238,312	3,694,865

## Our Properties

During the nine months ended September 30, 2021, we completed 16 acquisitions encompassing an aggregate of 541,496 leasable square feet for an aggregate contractual purchase price of \$163.2 million with an aggregate annualized base rent of \$12.2 million. As of September 30, 2021, our portfolio consisted of gross investment in real estate of \$1.3 billion, which was comprised of 102 facilities with an aggregate of 4.2 million leasable square feet and an aggregate \$100.8 million of annualized base rent.

## Capital Raising Activity

On March 18, 2021, we closed an underwritten public offering of our common stock, including the related option to purchase additional shares granted to the underwriters. These transactions resulted in the issuance of 8.6 million shares of our common stock at a public offering price of \$13.30 per share, generating gross proceeds of \$114.7 million.

During the nine months ended September 30, 2021, we generated gross proceeds of \$86.6 million through at-the-market (“ATM”) equity issuances of 6.1 million shares of our common stock at an average offering price of \$14.29 per share. As of November 1, 2021, we had \$23 million remaining under the 2020 ATM Program.



## Debt Activity

On May 3, 2021, we entered into an amended and restated credit facility (the "Credit Facility") to, among other things, (i) increase the overall capacity of the facility from \$600 million to \$750 million, consisting of a \$400 million revolver component (the "Revolver") and a \$350 million term loan component (the "Term Loan"), (ii) extend the term of the Revolver to May 2025, with two six-month extension options, and extend the maturity of the Term Loan component to May 2026, (iii) convert the facility from a secured to an unsecured facility and (iv) implement a new pricing matrix. The Credit Facility includes a \$500 million accordion feature. In addition, on May 4, 2021, we entered into five forward starting interest rate swaps that will fix the LIBOR component on the Term Loan through its maturity. Currently, our interest rate swaps fix the LIBOR component of the Term Loan at a rate of 1.91% through August 2023. Subsequently, from August 2023 to August 2024 the LIBOR component of the Term Loan rate will be fixed at 1.61%. Finally, from August 2024 to April 2026 the LIBOR component of the Term Loan rate will be fixed at 1.45%.

During the nine months ended September 30, 2021, we borrowed \$187.7 million under our Credit Facility and repaid \$207.2 million, for a net amount repaid of \$19.5 million. As of September 30, 2021, the net outstanding Credit Facility balance was \$497.2 million.

## Recent Developments

### *Completed Disposition Subsequent to September 30, 2021*

On October 13, 2021, we sold a medical office building located in Prescott, Arizona receiving gross proceeds of \$5.5 million, resulting in a gain of approximately \$1.1 million.

### *Properties Under Contract for Acquisition or Sale*

We have three properties under contract to acquire for an aggregate purchase price of approximately \$23.9 million. We are currently in the due diligence period for our properties under contract. If we identify problems with these properties or the operators of any properties during our due diligence review, we may not close the transactions on a timely basis or we may terminate the purchase agreements and not close the transactions.

On October 5, 2021, we entered into an agreement to sell a medical office building located in Belpre, Ohio for gross proceeds of approximately \$44.6 million. The property had a net book value of approximately \$29.7 million as of September 30, 2021. The transaction is expected to be completed no earlier than March 2022. The buyer is currently in the due diligence period and the transaction is subject to various closing contingencies. Accordingly, the transaction may not close on a timely basis or the buyer may terminate the purchase agreement and not close the transaction. We intend to reinvest the sales proceeds in 2022.

## Trends Which May Influence Our Results of Operations

We believe the following trends may positively impact our results of operations:

- *Growing healthcare expenditures.* According to the U.S. Department of Health and Human Services, overall healthcare expenditures are expected to grow at an average rate of 5.5% per year through 2027. We believe the long-term growth in healthcare expenditures will help maintain or increase the value of our healthcare real estate portfolio.
- *An aging population.* According to the 2010 U.S. Census, the segment of the population consisting of people 65 years or older comprise the fastest growing segment of the overall U.S. population. We believe this segment of the U.S. population will utilize many of the services provided at our healthcare facilities such as orthopedics, cardiac, gastroenterology and rehabilitation.
- *A continuing shift towards outpatient care.* According to the American Hospital Association, patients are demanding more outpatient operations. We believe this shift in patient preference from inpatient to outpatient facilities will benefit our tenants as most of our properties consist of outpatient facilities.
- *Physician practice group and hospital consolidation.* We believe the trend towards physician group consolidation will serve to strengthen the credit quality of our tenants if our tenants merge or are consolidated with larger health systems.

We believe the following trends may negatively impact our results of operations:

- *Increased competition for acquisition opportunities.* We face increased competition for our target asset classes from both private funds and other public REITs. Medical office properties have proven to be a resilient asset class during the COVID-19 pandemic as many tenants of such properties continued to pay rent during the pandemic, which was not the case for many other types of commercial real estate. Given the resiliency of medical office buildings, many real estate funds are now competing for acquisition opportunities in medical real estate, which will cause a decrease in overall capitalization rates and make it more difficult for us to locate acquisition opportunities that meet our investment and return criteria.
- *Continuation of the COVID-19 pandemic* – Although COVID-19 vaccines are currently being distributed and administered in the U.S., it is unclear when or if the COVID-19 pandemic will subside and the U.S. economy will recover. Although we do not believe the current state of the COVID-19 pandemic will negatively affect our ability to collect rents in the near term, a prolonged pandemic or resurgence of COVID-19, including any related variants of the COVID-19 virus such as the Delta variant, or others, could put additional strain on our tenants and could affect their ability to pay rents to us.
- *Changes in third party reimbursement methods and policies* Even prior to the COVID-19 pandemic, the price of healthcare services was increasing, and we believed that third-party payors, such as Medicare and commercial insurance companies, would continue to scrutinize and reduce the types of healthcare services eligible for, and the amounts of, reimbursement under their health insurance plans. Additionally, many employer-based insurance plans were continuing to increase the percentage of insurance premiums for which covered individuals are responsible. We expect these trends will only be exacerbated by the COVID-19 pandemic, as federal and state budgets are likely to be under tremendous stress due to the pandemic, which could affect government-sponsored insurance plans. If these trends continue, our tenants' businesses will continue to be negatively affected, which may impact their ability to pay rent to us.

#### **Critical Accounting Policy**

The preparation of financial statements in conformity with GAAP requires us to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our experience and on various other assumptions believed to be reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Please refer to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Commission on March 8, 2021, for further information regarding the critical accounting policies that affect our more significant estimates and judgments used in the preparation of our condensed consolidated financial statements included in Part I, Item 1 of this Report.

#### **Consolidated Results of Operations**

The major factors that resulted in variances in our results of operations for each revenue and expense category for the three and nine months ended September 30, 2021 compared to the same period in 2020 were the increase in the size of our property portfolio and our management internalization transaction that was completed in July 2020. Our total investments in real estate, net of accumulated depreciation and amortization, was \$1.2 billion and \$977.5 million as of September 30, 2021 and 2020, respectively.

**Three Months Ended September 30, 2021 Compared to Three Months Ended September 30, 2020**

	<b>Three Months Ended September 30,</b>		<b>\$ Change</b>
	<b>2021</b>	<b>2020</b>	
	(in thousands)		
<b>Revenue</b>			
Rental revenue	\$ 29,967	\$ 25,055	\$ 4,912
Other income	16	42	(26)
Total revenue	<u>29,983</u>	<u>25,097</u>	4,886
<b>Expenses</b>			
General and administrative	3,852	4,027	(175)
Operating expenses	3,973	3,619	354
Depreciation expense	8,639	6,954	1,685
Amortization expense	3,303	2,563	740
Interest expense	4,830	4,864	(34)
Management internalization expense	—	12,580	(12,580)
Preacquisition expense	18	70	(52)
Total expenses	<u>24,615</u>	<u>34,677</u>	(10,062)
Net income (loss)	<u>\$ 5,368</u>	<u>\$ (9,580)</u>	\$ 14,948

**Revenue****Total Revenue**

Total revenue for the three months ended September 30, 2021 was \$30.0 million, compared to \$25.1 million for the same period in 2020, an increase of \$4.9 million. The increase was primarily the result of rental revenue earned from the facilities that we acquired after September 30, 2020, as well as from the recognition of a full three months of rental revenue in 2021 from acquisitions that were completed during the three months ended September 30, 2020. Within that increase, \$3.2 million in revenue was recognized from net lease expense recoveries during the three months ended September 30, 2021, compared to \$3.1 million for the same period in 2020.

**Expenses****General and Administrative**

General and administrative expenses for the three months ended September 30, 2021 were \$3.9 million, compared to \$4.0 million for the same period in 2020, a decrease of \$0.1 million. The decrease resulted primarily from a reduction in non-cash LTIP compensation expense, which was \$1.2 million for the three months ended September 30, 2021, compared to \$1.6 million for the same period in 2020.

**Operating Expenses**

Operating expenses for the three months ended September 30, 2021 were \$4.0 million, compared to \$3.6 million for the same period in 2020, an increase of \$0.4 million. The increase resulted primarily from \$3.2 million of recoverable property operating expenses incurred during the three months ended September 30, 2021, compared to \$3.1 million for the same period in 2020. In addition, our operating expenses included \$0.5 million of property operating expenses from gross leases for the three months ended September 30, 2021, compared to \$0.4 million for the same period in 2020.

**Depreciation Expense**

Depreciation expense for the three months ended September 30, 2021 was \$8.6 million, compared to \$7.0 million for the same period in 2020, an increase of \$1.6 million. The increase resulted primarily from depreciation expense incurred on the facilities that we acquired after September 30, 2020, as well as from the recognition of a full three months of depreciation expense in 2021 from acquisitions that were completed during the three months ended September 30, 2020.

***Amortization Expense***

Amortization expense for the three months ended September 30, 2021 was \$3.3 million, compared to \$2.6 million for the same period in 2020, an increase of \$0.7 million. The increase resulted primarily from amortization expense incurred on intangible assets acquired after September 30, 2020, as well as from the recognition of a full three months of amortization expense in 2021 from intangible assets recorded during the three months ended September 30, 2020.

***Interest Expense***

Interest expense for the three months ended September 30, 2021 was \$4.8 million, compared to \$4.9 million for the same period in 2020, a decrease of \$0.1 million.

The weighted average interest rate of our debt for the three months ended September 30, 2021 was 3.04% compared to 3.32% for the three months ended September 30, 2020. Additionally, the weighted average interest rate and term of our debt was 2.91% and 4.53 years at September 30, 2021.

***Management Internalization Expense***

As a result of the completion of the management internalization transaction, we had no management internalization expense for the three months ended September 30, 2021. Management internalization expense was \$12.6 million for the three months ended September 30, 2020, which included \$12.1 million related to the settlement of a preexisting contractual relationship and \$0.5 million of professional fees associated with the transaction.

***Net Income (Loss)***

Net income for the three months ended September 30, 2021 was \$5.4 million, compared to a net loss of \$(9.6) million for the same period in 2020, an increase of \$15.0 million. The increase resulted primarily from the recognition of \$12.6 million of management internalization expense that was incurred during the three months ended September 30, 2020.

*Nine Months Ended September 30, 2021 Compared to Nine Months Ended September 30, 2020*

	Nine Months Ended September 30,		\$ Change
	2021	2020	
	(in thousands)		
<b>Revenue</b>			
Rental revenue	\$ 85,492	\$ 68,623	\$ 16,869
Other income	101	178	(77)
Total revenue	<u>85,593</u>	<u>68,801</u>	16,792
<b>Expenses</b>			
General and administrative	12,519	7,509	5,010
Operating expenses	10,964	8,256	2,708
Management fees – related party	—	4,024	(4,024)
Depreciation expense	24,779	19,383	5,396
Amortization expense	9,443	6,832	2,611
Interest expense	14,887	13,616	1,271
Management internalization expense	—	14,005	(14,005)
Preacquisition expense	146	267	(121)
Total expenses	<u>72,738</u>	<u>73,892</u>	(1,154)
Net income (loss)	<u>\$ 12,855</u>	<u>\$ (5,091)</u>	\$ 17,946

**Revenue*****Total Revenue***

Total revenue for the nine months ended September 30, 2021 was \$85.6 million, compared to \$68.8 million for the same period in 2020, an increase of \$16.8 million. The increase was primarily the result of rental revenue earned from the facilities we acquired subsequent to September 30, 2020, as well as from the recognition of a full nine months of rental revenue in 2021 from acquisitions that were completed during the nine months ended September 30, 2020. Within that increase, \$8.5 million in revenue was recognized from net lease expense recoveries during the nine months ended September 30, 2021, compared to \$6.9 million for the same period in 2020. Additionally, total revenue for the nine months ended September 30, 2020 reflected the recognition of reserves for approximately \$1.1 million of rent, including approximately \$0.4 million of deferred rent, primarily related to one tenant.

**Expenses*****General and Administrative***

General and administrative expenses for the nine months ended September 30, 2021 were \$12.5 million, compared to \$7.5 million for the same period in 2020, an increase of \$5.0 million. The increase was primarily driven by our recognition of compensation-related costs and other administrative expenses that prior to the management internalization transaction were the obligation of our former advisor. In addition, this increase was due to an increase in non-cash LTIP compensation expense, which was \$4.6 million for the nine months ended September 30, 2021, compared to \$3.4 million for the same period in 2020.

***Operating Expenses***

Operating expenses for the nine months ended September 30, 2021 were \$11.0 million, compared to \$8.3 million for the same period in 2020, an increase of \$2.7 million. The increase results from \$8.5 million of reimbursable property operating expenses incurred during the nine months ended September 30, 2021, compared to \$6.9 million for the same period in 2020. In addition, our operating expenses included \$1.5 million of property operating expenses from gross leases for the nine months ended September 30, 2021, compared to \$0.8 million for the same period in 2020.

***Management Fees Expense – related party***

As a result of the completion of the management internalization transaction, we incurred no management fee expense for the nine months ended September 30, 2021. Management fee expense was \$4.0 million for the nine months ended September 30, 2020 and was calculated based on our stockholders' equity balance.

***Depreciation Expense***

Depreciation expense for the nine months ended September 30, 2021 was \$24.8 million, compared to \$19.4 million for the same period in 2020, an increase of \$5.4 million. The increase results primarily from depreciation expense incurred on the facilities we acquired subsequent to September 30, 2020, as well as from the recognition of a full nine months of depreciation expense in 2021 from acquisitions that were completed during the nine months ended September 30, 2020.

***Amortization Expense***

Amortization expense for the nine months ended September 30, 2021 was \$9.4 million, compared to \$6.8 million for the same period in 2020, an increase of \$2.6 million. The increase results primarily from amortization expense incurred on intangible assets recorded subsequent to September 30, 2020, as well as from the recognition of a full nine months of amortization expense in 2021 from intangible assets recorded during the nine months ended September 30, 2020.

***Interest Expense***

Interest expense for the nine months ended September 30, 2021 was \$14.9 million, compared to \$13.6 million for the same period in 2020, an increase of \$1.3 million. This increase was primarily due to higher average borrowings during the nine months ended September 30, 2021, compared to the same period last year, the proceeds of which were used to finance our property acquisitions during that time period.

The weighted average interest rate of our debt for the nine months ended September 30, 2021 was 3.14% compared to 3.48% for the nine months ended September 30, 2020. Additionally, the weighted average interest rate and term of our debt was 2.91% and 4.53 years at September 30, 2021.

***Management Internalization Expense***

As a result of the completion of the management internalization transaction, we had no management internalization expense for the nine months ended September 30, 2021. Management internalization expense was \$14.0 million for the nine months ended September 30, 2020, which included \$12.1 million related to the settlement of a preexisting contractual relationship and \$1.9 million of professional fees associated with the transaction.

***Net Income (Loss)***

Net income for the nine months ended September 30, 2021 was \$12.9 million, compared to a net loss of \$(5.1) million for the same period in 2020, an increase of \$18.0 million. The increase resulted primarily from the recognition of \$14.0 million of management internalization expense that was incurred during the nine months ended September 30, 2020.

**Assets and Liabilities**

As of September 30, 2021 and December 31, 2020, our principal assets consisted of investments in real estate, net, of \$1.2 billion and \$1.0 billion, respectively. Our liquid assets consisted primarily of cash and cash equivalents and restricted cash of \$11.9 million and \$10.8 million, as of September 30, 2021 and December 31, 2020, respectively.

The increase in our investments in real estate, net, to \$1.2 billion as of September 30, 2021 compared to \$1.0 billion as of December 31, 2020, was the result of the 16 acquisitions that we completed during the nine months ended September 30, 2021.

The increase in our cash and cash equivalents and restricted cash balances to \$11.9 million as of September 30, 2021, compared to \$10.8 million as of December 31, 2020, was primarily due to net proceeds received from common equity offerings and net cash

provided by operating activities. Cash inflows were partially offset by funds used to acquire real estate, paydown debt, pay debt issuance costs related to the Credit Facility, and pay dividends to our common and preferred stockholders and OP Unit and LTIP Unit holders of our Operating Partnership.

The decrease in our total liabilities to \$613.1 million as of September 30, 2021 compared to \$643.1 million as of December 31, 2020, was primarily the result of debt repayments during 2021 and the resulting lower net borrowings outstanding.

## **Liquidity and Capital Resources**

### ***General***

Our short-term liquidity requirements include:

- Interest expense and scheduled principal payments on outstanding indebtedness;
- General and administrative expenses;
- Operating expenses;
- Property acquisitions; and
- Capital and tenant improvements.

In addition, we require funds for future distributions expected to be paid to our common and preferred stockholders and OP Unit and LTIP Unit holders in our Operating Partnership.

Our primary sources of cash include rent and reimbursements we collect from our tenants, borrowings under our Credit Facility, secured term loans, and net proceeds received from equity issuances. In addition, we may generate cash from property dispositions.

Our long-term liquidity needs consist primarily of funds necessary to pay for acquisitions, capital and tenant improvements at our properties, scheduled debt maturities, general and administrative expenses, operating expenses, and distributions. We expect to satisfy our short and long-term liquidity needs through various sources, including cash flow from operations, debt financing, sales of additional equity securities, the issuance of OP Units in connection with acquisitions of additional properties, proceeds from select property dispositions and joint venture transactions.

### ***Equity Issuances***

On March 18, 2021, we closed an underwritten public offering of our common stock, including the related option to purchase additional shares granted to the underwriters. These transactions resulted in the issuance of 8.6 million shares of our common stock at a public offering price of \$13.30 per share, generating gross proceeds of \$114.7 million.

During the nine months ended September 30, 2021, we generated gross proceeds of \$86.6 million through ATM equity issuances of 6.1 million shares of our common stock at an average offering price of \$14.29 per share. As of November 1, 2021, we had \$23 million remaining under the 2020 ATM Program.

### ***Debt Financing***

*Credit Facility.* As described in “Debt Activity,” the Credit Facility consists of a \$350 million Term Loan and a \$400 million Revolver. The Credit Facility also contains a \$500 million accordion. As of November 1, 2021, we had unutilized borrowing capacity under the Revolver of approximately \$240 million.

The Credit Facility is an unsecured facility with a term of four years for the Revolver (subject to two, six-month extension options) and a term of five years for the Term Loan. The Credit Facility also contains the following interest rate pricing grid:

Leverage Based Pricing	Revolver LIBOR Margin		Term Loan LIBOR Margin	
	Current	Prior	Current	Prior
< 40%	1.25%	N/A	1.20%	N/A
≥ 40% and < 45%	1.35%	1.40%	1.30%	1.35%
≥ 45% and < 50%	1.50%	1.65%	1.45%	1.60%
≥ 50 % and < 55%	1.75%	1.90%	1.70%	1.85%
≥ 55%	2.00%	2.15%	1.95%	2.10%

We are subject to a number of financial covenants under the Credit Facility, including, among other things, the following as of the end of each fiscal quarter, (i) a maximum consolidated unsecured leverage ratio of less than 60%, (ii) a maximum consolidated secured leverage ratio of less than 30%, (iii) a maximum consolidated secured recourse leverage ratio of less than 10%, (iv) a minimum fixed charge coverage ratio of 1.50:1.00, (v) a minimum unsecured interest coverage ratio of 1.50:1.00, (vi) a maximum consolidated leverage ratio of less than 60%, and (vii) a minimum net worth of \$345 million plus 75% of all net proceeds raised through equity offerings subsequent to December 31, 2020. As of November 1, 2021, management believed it was in compliance with all of the financial and non-financial covenants contained in the Credit Facility.

*Hedging Instruments.* We have six interest rate swaps with a total notional amount of \$350 million that are used to manage our interest rate risk and fix the LIBOR component on the Term Loan. An aggregate of \$150 million of the swaps mature in August 2023 and the remaining \$200 million mature in August 2024. In addition, we have five forward starting interest rate swaps that will be effective on the maturity dates of the existing interest rate swaps. The forward starting swaps each have a maturity date of April 2026 and will fix the LIBOR component on the Term Loan through its maturity. Currently, the interest rate swaps fix the LIBOR component of the Term Loan at a rate of 1.91% through August 2023. Subsequently, from August 2023 to August 2024 the LIBOR component of the Term Loan rate will be fixed at 1.61%. Finally, from August 2024 to April 2026 the LIBOR component of the Term Loan rate will be fixed at 1.45%.

*LIBOR Transition.* On March 5, 2021, the FCA announced that USD LIBOR will no longer be published after June 30, 2023. This announcement has several implications, including setting the spread that may be used to automatically convert contracts from LIBOR to SOFR. Additionally, banking regulators are encouraging banks to discontinue new LIBOR debt issuances by December 31, 2021. The Company anticipates that LIBOR will continue to be available at least until June 30, 2023. The Credit Facility provides that, on or about the LIBOR cessation date (subject to an early opt-in election), LIBOR shall be replaced as a benchmark rate in the Credit Facility with a new benchmark rate, with such adjustments as set forth in the Credit Facility. We are not able to predict when LIBOR will cease to be available or when there will be enough liquidity in the SOFR markets.

#### **Cash Flow Information**

Net cash provided by operating activities for the nine months ended September 30, 2021 was \$51.7 million, compared to \$18.4 million for the same period in 2020. The increase during the 2021 period was primarily due to the increase in net income as well as increases in depreciation and amortization expenses for the nine months ended September 30, 2021 compared to the same period in 2020.

Net cash used in investing activities for the nine months ended September 30, 2021 was \$166.7 million, compared to \$141.6 million for the same period in 2020. The increase during the 2021 period was primarily the result of greater real estate investment activity in the 2021 period compared to the same period in 2020.

Net cash provided by financing activities for the nine months ended September 30, 2021 was \$116.2 million, compared to \$123.3 million for the same period in 2020. The decrease was primarily due to net repayments on the Credit Facility, principal payments on our notes payable, the payment of debt issuance costs related to the Credit Facility, and higher dividends paid to our common stockholders, partially offset by net proceeds received from our common stock offerings.

#### **Non-GAAP Financial Measures**

Management considers certain non-GAAP financial measures to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in



accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial measures. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of those measures to the most directly comparable GAAP financial measure.

The non-GAAP financial measures presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q.

*Funds from Operations and Adjusted Funds from Operations*

Funds from operations ("FFO") and adjusted funds from operations ("AFFO") are non-GAAP financial measures within the meaning of the rules of the SEC. The Company considers FFO and AFFO to be important supplemental measures of its operating performance and believes FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results.

In accordance with the National Association of Real Estate Investment Trusts' ("NAREIT") definition, FFO means net income or loss computed in accordance with GAAP before noncontrolling interests of holders of OP Units and LTIP Units, excluding gains (or losses) from sales of property and extraordinary items, less preferred stock dividends, plus real estate-related depreciation and amortization (excluding amortization of debt issuance costs and the amortization of above and below market leases), and after adjustments for unconsolidated partnerships and joint ventures. Because FFO excludes real estate-related depreciation and amortization (other than amortization of debt issuance costs and above and below market lease amortization expense), the Company believes that FFO provides a performance measure that, when compared period-over-period, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from the closest GAAP measurement, net income or loss.

AFFO is a non-GAAP measure used by many investors and analysts to measure a real estate company's operating performance by removing the effect of items that do not reflect ongoing property operations. Management calculates AFFO by modifying the NAREIT computation of FFO by adjusting it for certain cash and non-cash items and certain recurring and non-recurring items. For the Company these items include recurring acquisition and disposition costs, loss on the extinguishment of debt, recurring straight line deferred rental revenue, recurring stock-based compensation expense, recurring amortization of above and below market leases, recurring amortization of debt issuance costs, recurring lease commissions, management internalization costs, and other items.

Management believes that reporting AFFO in addition to FFO is a useful supplemental measure for the investment community to use when evaluating the operating performance of the Company on a comparative basis.

A reconciliation of net income (loss) to FFO and AFFO for the three and nine months ended September 30, 2021 and 2020 is as follows:

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2021</b>	<b>2020</b>	<b>2021</b>	<b>2020</b>
	(unaudited, in thousands except per share and unit amounts)			
<b>Net income (loss)</b>	<b>\$ 5,368</b>	<b>\$ (9,580)</b>	<b>\$ 12,855</b>	<b>\$ (5,091)</b>
Less: Preferred stock dividends	(1,455)	(1,455)	(4,366)	(4,366)
Depreciation and amortization expense	11,915	9,517	34,140	26,215
<b>FFO</b>	<b>\$ 15,828</b>	<b>\$ (1,518)</b>	<b>\$ 42,629</b>	<b>\$ 16,758</b>
Internalization expense - settlement of a preexisting contractual relationship	—	12,094	—	12,094
Internalization expense - other transaction costs	—	486	—	1,911
Amortization of above market leases, net	173	69	318	472
Straight line deferred rental revenue	(1,369)	(1,520)	(4,147)	(4,336)
Stock-based compensation expense	1,241	1,572	4,568	3,391
Amortization of debt issuance costs and other	538	396	1,468	1,030
Preacquisition expense	18	70	146	267
<b>AFFO</b>	<b>\$ 16,429</b>	<b>\$ 11,649</b>	<b>\$ 44,982</b>	<b>\$ 31,587</b>
<b>Net income (loss) attributable to common stockholders per share – basic and diluted</b>	<b>\$ 0.06</b>	<b>\$ (0.22)</b>	<b>\$ 0.13</b>	<b>\$ (0.19)</b>
<b>FFO per share and unit</b>	<b>\$ 0.23</b>	<b>\$ (0.03)</b>	<b>\$ 0.67</b>	<b>\$ 0.34</b>
<b>AFFO per share and unit</b>	<b>\$ 0.24</b>	<b>\$ 0.23</b>	<b>\$ 0.71</b>	<b>\$ 0.65</b>
Weighted Average Shares and Units Outstanding – basic and diluted	68,109	50,233	63,179	48,896
<b>Weighted Average Shares and Units Outstanding:</b>				
Weighted Average Common Shares	64,204	46,908	59,398	45,503
Weighted Average OP Units	1,707	1,958	1,741	2,250
Weighted Average LTIP Units	2,198	1,367	2,040	1,143
Weighted Average Shares and Units Outstanding – basic and diluted	68,109	50,233	63,179	48,896

*Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate (EBITDAre and Adjusted EBITDAre)*

The Company calculates EBITDAre in accordance with standards established by NAREIT and define EBITDAre as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, gain or loss on the sale of investment properties, and impairment loss, as applicable. The Company defines Adjusted EBITDAre as EBITDAre plus non-cash stock compensation expense, non-cash intangible amortization related to above and below market leases, preacquisition expense and other normalizing items. Management considers EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

A reconciliation of net income (loss) to EBITDAre and Adjusted EBITDAre for the three and nine months ended September 30, 2021 and 2020 is as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2020	2021	2020
	(unaudited and in thousands)			
<b>Net income (loss)</b>	<b>\$ 5,368</b>	<b>\$ (9,580)</b>	<b>\$ 12,855</b>	<b>\$ (5,091)</b>
Interest expense	4,830	4,864	14,887	13,616
Depreciation and amortization expense	11,942	9,517	34,222	26,215
<b>EBITDAre</b>	<b>\$ 22,140</b>	<b>\$ 4,801</b>	<b>\$ 61,964</b>	<b>\$ 34,740</b>
Stock-based compensation expense	1,241	1,572	4,568	3,391
Internalization expense - settlement of a preexisting contractual relationship	—	12,094	—	12,094
Internalization expense - other transaction costs	—	486	—	1,911
Amortization of above market leases, net	173	69	318	472
Preacquisition expense	18	70	146	267
<b>Adjusted EBITDAre</b>	<b>\$ 23,572</b>	<b>\$ 19,092</b>	<b>\$ 66,996</b>	<b>\$ 52,875</b>

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

### Inflation

Historically, inflation has had a minimal impact on the operating performance of our healthcare facilities. Many of our triple-net lease agreements contain provisions designed to mitigate the adverse impact of inflation. These provisions include clauses that enable us to receive payment of increased rent pursuant to escalation clauses which generally increase rental rates during the terms of the leases. These escalation clauses often provide for fixed rent increases or indexed escalations (based upon the CPI or other measures). However, some of these contractual rent increases may be less than the actual rate of inflation. Most of our triple-net lease agreements require the tenant-operator to pay an allocable share of operating expenses, including common area maintenance costs, real estate taxes and insurance. This requirement reduces our exposure to increases in these costs and operating expenses resulting from inflation.

### Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Market risk includes risks that arise from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices and other market changes that affect market sensitive instruments. In pursuing our business and investment objectives, we expect that the primary market risk to which we will be exposed is interest rate risk.

We may be exposed to the effects of interest rate changes primarily as a result of debt used to acquire healthcare facilities, including borrowings under the Credit Facility. The analysis below presents the sensitivity of the value of our variable rate financial obligations to selected changes in market interest rates. The range of changes chosen reflects our view of changes which are reasonably possible over a one-year period.

As of September 30, 2021, we had \$155.7 million of unhedged floating-rate borrowings outstanding (before the netting of unamortized debt issuance costs). At September 30, 2021, LIBOR on our outstanding floating-rate borrowings was 0.11%. Assuming no increase in the amount of our floating-rate debt, if LIBOR increased 100 basis points, our cash flow would decrease by approximately \$1.6 million annually. Assuming no increase in the amount of our floating-rate debt, if LIBOR were reduced 100 basis points, our cash flow would increase by approximately \$1.6 million annually.

Our interest rate risk management objectives are to limit the impact of interest rate changes on earnings and cash flows and to lower overall borrowing costs. To achieve our objectives, we may borrow at fixed rates or floating rates. We have six interest rate swaps with a total notional amount of \$350 million that are used to manage our interest rate risk and fix the LIBOR component on the Term Loan. An aggregate of \$150 million of the swaps mature in August 2023 and the remaining \$200 million mature in August 2024. In

addition, we have five forward starting interest rate swaps that will be effective on the maturity dates of the existing interest rate swaps. The forward starting swaps each have a maturity date of April 2026 and will fix the LIBOR component on the Term Loan through its maturity. Currently, the interest rate swaps fix the LIBOR component of the Term Loan at a rate of 1.91% through August 2023. Subsequently, from August 2023 to August 2024 the LIBOR component of the Term Loan rate will be fixed at 1.61%. Finally, from August 2024 to April 2026 the LIBOR component of the Term Loan rate will be fixed at 1.45%.

We may enter into additional derivative financial instruments, including interest rate swaps and caps, in order to mitigate our interest rate risk on our future borrowings. We will not enter into derivative transactions for speculative purposes.

In addition to changes in interest rates, the value of our investments is subject to fluctuations based on changes in local and regional economic conditions and changes in the creditworthiness of tenants/operators and borrowers, which may affect our ability to refinance our debt if necessary.

#### **Item 4. Controls and Procedures.**

##### **Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act that are designed to ensure that information required to be disclosed in our reports filed or submitted to the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC's rules and forms, and that information is accumulated and communicated to management, including the principal executive and financial officer as appropriate, to allow timely decisions regarding required disclosures. Our principal executive officer and principal financial officer evaluated the effectiveness of disclosure controls and procedures as of September 30, 2021 pursuant to Rule 13a-15(b) under the Exchange Act. Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this Report, the Company's disclosure controls and procedures were effective to ensure that information required to be included in our periodic SEC filings is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms.

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

##### **Changes in Internal Control over Financial Reporting**

No changes were made to our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## **PART II OTHER INFORMATION**

#### **Item 1. Legal Proceedings**

We are not involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties is subject, which would reasonably be likely to have a material adverse effect on our financial condition or results of operations. From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. There can be no assurance that these matters that arise in the future, individually or in the aggregate, will not have a material adverse effect on our financial condition or results of operations in any future period.

#### **Item 1A. Risk Factors**

During the nine months ended September 30, 2021, there were no material changes to the risk factors that were disclosed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 8, 2021

other than the risk factor disclosed in Item 1A. Risk Factors of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, that was filed with the SEC on May 7, 2021.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

On August 6, 2021, the Company issued 11,004 shares of its common stock to Charles F. Brown (“Brown”) in connection with Brown’s redemption of 11,004 OP Units issued to him by the Operating Partnership on December 31, 2018 in connection with Brown’s contribution of certain assets to the Operating Partnership. Pursuant to the terms of the Operating Partnership’s partnership agreement, OP Units may be redeemed by the holder after a one-year holding period for either cash or shares of common stock of the Company, such form of redemption consideration to be determined at the sole discretion of the Company. The issuance of these shares of common stock was effected in reliance upon the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, based on the fact that the issuance was not a “public offering” as defined in Section 4(a)(2) due to the insubstantial number of persons involved in the transaction, manner of the issuance and number of securities issued.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

None.

**Item 6. Exhibits**

<b>(a) Exhibits</b>	
<b>Exhibit No.</b>	<b>Description</b>
3.1	<a href="#">Articles of Restatement of Global Medical REIT Inc. (incorporated herein by reference to Exhibit 3.1 to the Company's Report on Form 10-Q as filed with the SEC on August 8, 2018).</a>
3.2	<a href="#">Third Amended and Restated Bylaws of Global Medical REIT Inc., adopted as of August 13, 2019 (incorporated herein by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K as filed with the SEC on August 14, 2019).</a>
4.1	<a href="#">Specimen of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-11/A as filed with the SEC on June 15, 2016).</a>
4.2	<a href="#">Specimen of 7.50% Series A Cumulative Redeemable Preferred Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K as filed with the SEC on September 14, 2017).</a>
31.1*	<a href="#">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
31.2*	<a href="#">Certification of Principal Financial and Accounting Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
32.1**	<a href="#">Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
101.INS *	Inline XBRL Instance Document
101.SCH *	Inline XBRL Taxonomy Schema
101.CAL *	Inline XBRL Taxonomy Calculation Linkbase
101.DEF *	Inline XBRL Taxonomy Definition Linkbase
101.LAB *	Inline XBRL Taxonomy Label Linkbase
101.PRE *	Inline XBRL Taxonomy Presentation Linkbase
104	Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101)

---

\* Filed herewith.

\*\* Furnished herewith. Such certification shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**GLOBAL MEDICAL REIT INC.**

Date: November 5, 2021

By: /s/ Jeffrey M. Busch  
Jeffrey M. Busch  
Chief Executive Officer (Principal Executive Officer)

Date: November 5, 2021

By: /s/ Robert J. Kiernan  
Robert J. Kiernan  
Chief Financial Officer (Principal Financial and Accounting Officer)

## CERTIFICATIONS

I, Jeffrey M. Busch, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2021 of Global Medical REIT Inc. (the “registrant”)
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2021

*/s/ Jeffrey M. Busch*

\_\_\_\_\_  
Jeffrey M. Busch, Chief Executive Officer  
(Principal Executive Officer)

---



## CERTIFICATIONS

I, Robert J. Kiernan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2021 of Global Medical REIT Inc. (the “registrant”)
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2021

/s/ Robert J. Kiernan  
Robert J. Kiernan, Chief Financial Officer  
(Principal Financial and Accounting Officer)

---

**Section 1350 Certification of Chief Executive Officer and Chief Financial Officer**

In connection with the Quarterly Report on Form 10-Q of Global Medical REIT Inc. (the "Company") for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jeffrey M. Busch, Chief Executive Officer of the Company and I, Robert J. Kiernan, Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 5, 2021

/s/ Jeffrey M. Busch

Jeffrey M. Busch, Chief Executive Officer  
(Principal Executive Officer)

Date: November 5, 2021

/s/ Robert J. Kiernan

Robert J. Kiernan, Chief Financial Officer  
(Principal Financial and Accounting Officer)

*This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.*

---